| P7464 | Genetics Home Reference Conditions ID | primary-myelofibrosis |
| P2671 | Google Knowledge Graph ID | /g/1q6h_y5bv |
| P1748 | NCI Thesaurus ID | C2862 |
| P2892 | UMLS CUI | C0001815 |
| Q66071494 | 18F-FLT (PET/CT) in Pediatrics With Myeloproliferative Neoplasms |
| Q66046180 | 18F-FLT (PET/CT) in Prefibrotic/Early Primary Myelofibrosis and Essential Thrombocythemia |
| Q65387965 | 3-AP and Fludarabine in Treating Patients With Myeloproliferative Disorders, Chronic Myelomonocytic Leukemia, or Accelerated Phase or Blastic Phase Chronic Myelogenous Leukemia |
| Q64221350 | A Clinical Study of Ruxolitinib in Patients With Primary Myelofibrosis (PM), Post-polycythemia Vera (PV) Myelofibrosis, or Post-essential Thrombocythemia (ET) Myelofibrosis |
| Q63229187 | A Clinical Study to Test the Effects of Ruxolitinib And Thalidomide Combination for Patients With Myelofibrosis |
| Q64721537 | A Dose-escalation Study of the Safety and Tolerability of Orally Administered TG101348 in Patients With Myelofibrosis |
| Q64716943 | A Long-Term Study of the Effects of Orally Administered SAR302503 in Patients With Myelofibrosis |
| Q64697472 | A Phase 1 Dose Escalation Study of TAK-901 in Subjects With Advanced Hematologic Malignancies |
| Q61979901 | A Phase 1 Study of MKC-1 in Patients With Refractory Hematologic Malignancies |
| Q63579075 | A Phase 1 Trial of CD25/Treg-depleted DLI Plus Ipilimumab for Myeloid Disease Relapse After Matched-HCT |
| Q64396797 | A Phase 1/2 Study To Evaluate ASN002 In Relapsed/Refractory Lymphoma And Advanced Solid Tumors |
| Q63062220 | A Phase 1/2 Study of Oral SB1518 in Subjects With Chronic Idiopathic Myelofibrosis |
| Q64717828 | A Phase 1/2 Study of SB1518 for the Treatment of Advanced Myeloid Malignancies |
| Q64352409 | A Phase 2 Study Of PRM-151 In Subjects With Myelofibrosis |
| Q63813009 | A Phase 2 Study With IPI-926 in Patients With Myelofibrosis |
| Q65355231 | A Phase 2 Study of CPI-0610 With and Without Ruxolitinib in Patients With Myelofibrosis |
| Q64217547 | A Phase II Non-Controlled, Open-Label, Efficacy, Safety, Pharmacokinetic, and Pharmacodynamic Study of Pacritinib in Myelofibrosis |
| Q62110386 | A Phase II Study of CC-5013 in Myelofibrosis |
| Q65383931 | A Phase II Study of Pomalidomide in Myelofibrosis With Myeloid Metaplasia |
| Q64220587 | A Phase II Study of Re-treatment of Myelofibrosis Patients With Ruxolitinib/Jakavi After Treatment Interruption Due to Loss of Response and/or Adverse Event (ReTreatment Trial) |
| Q64635812 | A Phase Ib/II Dose-finding Study to Assess the Safety and Efficacy of LDE225 + INC424 in Patients With MF |
| Q65382343 | A Safety Study of XL019 in Adults With Myelofibrosis |
| Q66043209 | A Safety and Efficacy Study to Evaluate Luspatercept in Subjects With Myeloproliferative Neoplasm-associated Myelofibrosis Who Have Anemia With and Without Red Blood Cell-transfusion Dependence |
| Q100789258 | A Study Comparing Imetelstat Versus Best Available Therapy for the Treatment of Intermediate-2 or High-risk Myelofibrosis (MF) Who Have Not Responded to Janus Kinase (JAK)-Inhibitor Treatment |
| Q66069338 | A Study Evaluating Tolerability and Efficacy of Navitoclax in Combination With Ruxolitinib in Subjects With Myelofibrosis |
| Q63834477 | A Study in Myeloproliferative Disorders |
| Q92271850 | A Study of APG-1252 and APG-1387 in Patients With Myelofibrosis Who Progressed After Initial Therapy |
| Q66029322 | A Study of Gleevec in Patients With Idiopathic Myelofibrosis or Chronic Myelomonocytic Leukemia (CMML) |
| Q63573343 | A Study of Itacitinib in Combination With Low-Dose Ruxolitinib or Itacitinib Alone Following Ruxolitinib in Subjects With Myelofibrosis |
| Q64650668 | A Study of Low Dose Interferon Alpha Versus Hydroxyurea in Treatment of Chronic Myeloid Neoplasms |
| Q76981720 | A Study of Momelotinib Versus Danazol in Symptomatic and Anemic Myelofibrosis Patients |
| Q76981511 | A Study of Oral TP-3654 in Patients With Myelofibrosis |
| Q63581491 | A Study of PRT543 in Participants With Advanced Solid Tumors and Hematologic Malignancies |
| Q74282166 | A Study of PRT811 in Participants With Advanced Solid Tumors, Gliomas and Myelofibrosis |
| Q66407547 | A Study of Parsaclisib in Combination With Ruxolitinib in Subjects With Myelofibrosis |
| Q107213794 | A Study to Assess the Safety and Tolerability of BMS-986158 Alone and in Combination With Either Ruxolitinib or Fedratinib in Participants With Blood Cancer (Myelofibrosis) |
| Q76984069 | A Study to Evaluate Long-term Safety in Subjects Who Have Participated in Other Luspatercept (ACE-536) Clinical Trials |
| Q100789570 | A Study to Evaluate Safety and Efficacy of Selinexor Versus Treatment of Physician's Choice in Participants With Previously Treated Myelofibrosis |
| Q100789605 | A Study to Evaluate Safety and Efficacy of Selinexor in Combination With Ruxolitinib in Participants With Myelofibrosis |
| Q64216899 | A Study to Evaluate the Efficacy and Safety of Vismodegib in Combination With Ruxolitinib for the Treatment of Intermediate- or High-Risk Myelofibrosis (MF) |
| Q104676430 | A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral GB2064 in Participants With Myelofibrosis |
| Q64651224 | A Study to Find the Maximum Tolerated Dose of the Experimental Combination of the Drugs INC424 and BKM120 in Patients With Primary or Secondary Myelofibrosis |
| Q65537508 | A Trial of Zoledronic Acid in Patients With Myelofibrosis With Myeloid Metaplasia (MMM) |
| Q64649715 | A Two-Step Approach to Reduced Intensity Bone Marrow Transplant for Patients With Hematological Malignancies |
| Q62040406 | AZD1775 in Advanced Acute Myeloid Leukemia, Myelodysplastic Syndrome and Myelofibrosis |
| Q83794876 | Actuate 1901: 9-ING-41 in Myelofibrosis |
| Q65335657 | Alisertib in Treating Patients With Myelofibrosis or Relapsed or Refractory Acute Megakaryoblastic Leukemia |
| Q64723879 | Allogeneic Stem Cell Transplantation (SCT) After Dose-reduced Conditioning for Myelofibrosis Patients |
| Q64170969 | Allogeneic Stem Cell Transplantation for Myelofibrosis and Myelodysplastic Syndrome |
| Q63321638 | Alternative Dosing Strategy of Ruxolitinib in Patients With Myelofibrosis |
| Q64121907 | An Efficacy and Safety Study of Fedratinib Compared to Best Available Therapy in Subjects With DIPSS-intermediate or High-risk Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, or Post-essential Thrombocythemia Myelofibrosis and Previ |
| Q63594153 | An Efficacy and Safety Trial of Fedratinib in Subjects With DIPSS, Intermediate or High-Risk Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis and Previously Treated With Ruxolitinib |
| Q65373023 | An Open Label Study of Itacitinib Administered Orally in Patients With Myelofibrosis |
| Q107214320 | An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 Combined With Ruxolitinib in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera MF (Post-PV-MF), Or Post-Essential Thrombocythemia MF (Post ET-MF) |
| Q63814063 | Anti-TGF-beta Therapy in Patients With Myelofibrosis |
| Q64659405 | Arsenic Trioxide With or Without Ascorbic Acid in Treating Patients With Myelofibrosis |
| Q65539351 | Arsenic Trioxide, Ascorbic Acid, Dexamethasone, and Thalidomide in Myelofibrosis/Myeloproliferative Disorder |
| Q64649966 | Asian Phase II Study of INC424 in Patients With Primary Myelofibrosis (MF), Post-PV MF or Post-ET MF |
| Q63805315 | Assess the Safety, Tolerability Oral PU-H71 in Subjects Taking Ruxolitinib |
| Q86260257 | Assessing Feasibility of Thromboprophylaxis With Apixaban in JAK2-positive Myeloproliferative Neoplasm Patients |
| Q63337562 | Assessment of Labile Plasma Iron (LPI) in Myelodysplastic Syndromes (MDS) and Primary Myelofibrosis |
| Q61894499 | Azacitidine and Sonidegib or Decitabine in Treating Patients With Myeloid Malignancies |
| Q65387943 | Azacitidine in Treating Patients With Myelofibrosis |
| Q63577998 | Azacitidine, Venetoclax, and Pevonedistat in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia |
| Q64698943 | Basiliximab #2: In-Vivo Activated T-Cell Depletion to Prevent Graft-Versus_Host Disease (GVHD) After Nonmyeloablative Allotransplantation for the Treatment of Blood Cancer |
| Q61918165 | Beclomethasone Dipropionate in Preventing Acute Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant for Hematologic Cancer |
| Q65387745 | Belinostat and Azacitidine in Treating Patients With Advanced Hematologic Cancers or Other Diseases |
| Q63814182 | Bioequivalence Trial of Luitpold Azacitidine Versus Vidaza® in Patients With Myelodysplastic Syndrome, Myelofibrosis, Chronic Myeloid Leukemia or Chronic Lymphocytic Leukemia |
| Q64717108 | Bone Marrow Transplant Chart Review for RIC |
| Q63837790 | Bone Marrow and Kidney Transplant for Patients With Chronic Kidney Disease and Blood Disorders |
| Q64724234 | Busulfan, Cyclophosphamide, and Antithymocyte Globulin Followed by Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer |
| Q63811541 | Busulfan, Fludarabine, Donor Stem Cell Transplant, and Cyclophosphamide in Treating Patients With Multiple Myeloma or Myelofibrosis |
| Q63398193 | CALR Exon 9 Mutant Peptide Vaccine to Patients With CALR-mutant Myeloproliferative Neoplasms |
| Q64047995 | CC-4047 in Treating Patients With Myelofibrosis |
| Q64048217 | CEP-701 (Lestaurtinib) in Myelofibrosis |
| Q61917673 | CEP-701 for PH-negative Myelofibrosis |
| Q64795627 | CMV-MVA Triplex Vaccination of Stem Cell Donors in Preventing CMV Viremia in Participants With Blood Cancer Undergoing Donor Stem Cell Transplant |
| Q64665012 | COntrolled MyeloFibrosis Study With ORal JAK Inhibitor Treatment: The COMFORT-I Trial |
| Q66075401 | Calcineurin Inhibitor-Free GVHD Prevention Regimen After Related Haplo PBSCT |
| Q65465810 | Cell Cycle Regulatory Gene Study in Patients With Myeloproliferative Disorders |
| Q66034098 | Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Myelofibrosis |
| Q63829957 | Clinical Trial of Aplidin® in Patients With Primary Myelofibrosis |
| Q64187565 | Clinical and Pathophysiological Investigations Into Erdheim Chester Disease |
| Q66045876 | Combination Chemotherapy, Total Body Irradiation, and Donor Blood Stem Cell Transplant in Treating Patients With Secondary Myelofibrosis |
| Q66071221 | Combination of JAK2 Inhibitor and Erythropoiesis-stimulating Agent in Myelofibrosis |
| Q87930201 | Combined Ruxolitinib and Enasidenib in Patients With Accelerated/Blast-phase Myeloproliferative Neoplasm or Chronic-phase Myelofibrosis With an IDH2 Mutation |
| Q61907523 | Comparing ATG or Post-Transplant Cyclophosphamide to Calcineurin Inhibitor-Methotrexate as GVHD Prophylaxis After Myeloablative Unrelated Donor Peripheral Blood Stem Cell Transplantation |
| Q64673416 | Controlled Myelofibrosis Study With Oral Janus-associated Kinase (JAK) Inhibitor Treatment-II: The COMFORT-II Trial |
| Q64720035 | Correlative Biomarker Study in Patients With Myeloproliferative Disorders |
| Q66028983 | Creation of Bone Marrow Microenvironment for Treatment of Myelodysplastic Syndrome (MDS) in Conjunction With Allogeneic Stem Cell Transplantation |
| Q61924544 | Cyclophosphamide and Busulfan Followed by Donor Stem Cell Transplant in Treating Patients With Myelofibrosis, Acute Myeloid Leukemia, or Myelodysplastic Syndrome |
| Q64188812 | Dasatinib as Therapy for Myeloproliferative Disorders (MPDs) |
| Q87930141 | Decitabine With Ruxolitinib or Fedratinib for the Treatment of Accelerated/Blast Phase Myeloproliferative Neoplasms |
| Q64188825 | Decitabine in Treating Patients With Myelofibrosis |
| Q63834695 | Deferasirox for Treating Patients Who Have Undergone Allogeneic Stem Cell Transplant and Have Iron Overload |
| Q63815432 | Deferasirox in Treating Iron Overload Caused By Blood Transfusions in Patients With Hematologic Malignancies |
| Q63405398 | Defining the Molecular Risk in Israeli Patients With Secondary Compared to Primary Myelofibrosis |
| Q66403835 | Determine Pacritinib Pharmacokinetics in Impaired Hepatic Patients and Healthy Subjects |
| Q61936868 | Donor Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies |
| Q61908774 | Dose-Finding Study of Pacritinib in Patients With Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis Previously Treated With Ruxolitinib |
| Q66083937 | Durvalumab in Treating Patients With Primary, Post-Polycythemia Vera, or Post-Essential Thrombocythemia Myelofibrosis |
| Q64140078 | Efficacy and Safety of Ruxolitinib in the Treatment of Anemic Myelofibrosis Patients. |
| Q64649955 | Efficacy and Safety of Simtuzumab in Adults With Primary, Post Polycythemia Vera or Post Essential Thrombocythemia Myelofibrosis |
| Q64219858 | Efficacy of Momelotinib Versus Best Available Therapy in Anemic or Thrombocytopenic Subjects With Primary Myelofibrosis (MF), Post-polycythemia Vera MF, or Post-essential Thrombocythemia MF |
| Q63320538 | Eltrombopag for the Management of Thrombocytopenia Associated With Tyrosine Kinase Therapy in Patients With Chronic Myeloid Leukemia (CML) and Myelofibrosis (MF) |
| Q74133227 | European Registry for Myeloproliferative Neoplasms (MPNs) - Update of ERNEST Study |
| Q64805914 | Evaluation of Ruxolitinib in Combination With PU-H71 for Treatment of Myelofibrosis |
| Q65543760 | Expanded Access of Deferasirox to Patients With Congenital Disorders of Red Blood Cells and Chronic Iron Overload |
| Q63395106 | Expanded Access to Navitoclax |
| Q65374498 | Exploratory Phase II Study of INC424 Patients With Primary Myelofibrosis (PMF) or Post Polycythaemia Myelofibrosis (PPV MF) or Post Essential Thrombocythaemia Myelofibrosis (PET-MF) |
| Q63401017 | Extended Access of Momelotinib in Adults With Myelofibrosis |
| Q63340642 | Extension Study Evaluating the Long Term Safety and Efficacy Study of CYT387 in Primary Myelofibrosis (PMF) or Post-polycythemia Vera (PV) or Post-essential Thrombocythemia (ET) |
| Q64719838 | Familial Myeloproliferative Disorders |
| Q64648694 | Fludarabine Based Conditioning for Allogeneic Transplantation for Advanced Hematologic Malignancies |
| Q64170972 | Fludarabine Phosphate and Total Body Irradiation Followed by a Donor Peripheral Stem Cell Transplant in Treating Patients With Myelodysplastic Syndromes or Myeloproliferative Disorders |
| Q64790128 | Fludarabine Phosphate, Cyclophosphamide, Total Body Irradiation, and Donor Stem Cell Transplant in Treating Patients With Blood Cancer |
| Q64679286 | Fludarabine Phosphate, Melphalan, Total-Body Irradiation, Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer or Bone Marrow Failure Disorders |
| Q64672690 | Fludarabine Phosphate, Melphalan, and Low-Dose Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies |
| Q62105038 | Fludarabine and Total-Body Irradiation Followed By Donor Stem Cell Transplant and Cyclosporine and Mycophenolate Mofetil in Treating HIV-Positive Patients With or Without Cancer |
| Q105088749 | Fostamatinib as a Single Agent or in Combination With Ruxolitinib for Treatment of Patients With Myelofibrosis With Severe Thrombocytopenia |
| Q66034705 | Genetic Analysis of Gray Platelet Syndrome |
| Q63401349 | HLA-Haploidentical SCT+ Post SCT Cy for Advanced Myelofibrosis |
| Q64642217 | HSP90 Inhibitor, AUY922, in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (Post-PV MF), Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF), and Refractory PV/ET |
| Q62811497 | Haploidentical Allogeneic Peripheral Blood Transplantation: Examining Checkpoint Immune Regulators' Expression |
| Q63807899 | Hu8F4 in Treating Patients With Advanced Hematologic Malignancies |
| Q66066203 | Hyperbaric Oxygen Therapy and Allogeneic Peripheral Blood Stem Cell (PBSC) Transplant |
| Q66043745 | IMG-7289 in Patients With Myelofibrosis |
| Q63319936 | INC424 for Patients With Primary Myelofibrosis, Post Polycythemia Myelofibrosis or Post-essential Thrombocythemia Myelofibrosis. |
| Q97461686 | INCB000928 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Anemia Due to Myeloproliferative Disorders |
| Q64353584 | Identification of Mechanism in the Erythroid Response in Patients With Myelodysplasia Undergoing Chelation Therapy |
| Q66036643 | Imatinib Mesylate in Treating Patients With Advanced Cancer and Liver Dysfunction |
| Q65542198 | Imatinib Mesylate in Treating Patients With Myelofibrosis |
| Q86254441 | Imatinib Mesylate in Treating Patients With Myelofibrosis (2002-04-30) |
| Q65372606 | Imetelstat Sodium in Treating Patients With Primary or Secondary Myelofibrosis |
| Q64724761 | In-Vivo Activated T-Cell Depletion to Prevent GVHD |
| Q63597931 | Individual Patient Compassionate Use of Fedratinib |
| Q63572918 | Infection Prophylaxis and Management in Treating Cytomegalovirus (CMV) Infection in Patients With Hematologic Malignancies Previously Treated With Donor Stem Cell Transplant |
| Q107974184 | Interest of CALR Allele Burden in Diagnosis and Follow-up of Patients With CALR Mutated Myeloproliferative Syndromes (CALRSUIVI) |
| Q66081351 | Interferon-pegyle α2a Efficiency and Tolerance in Myelofibrosis |
| Q64709171 | Internet-Based Program With or Without Telephone-Based Problem-Solving Training in Helping Long-Term Survivors of Hematopoietic Stem Cell Transplant Cope With Late Complications |
| Q64608846 | Intra-Osseous Co-Transplant of UCB and hMSC |
| Q90693368 | Itacitinib, Tacrolimus, and Sirolimus for the Prevention of GVHD in Patients With Acute Leukemia, Myelodysplastic Syndrome, or Myelofibrosis Undergoing Reduced Intensity Conditioning Donor Stem Cell Transplantation |
| Q64602197 | JAK Inhibitor Before Donor Stem Cell Transplant in Treating Patients With Primary or Secondary Myelofibrosis |
| Q65369618 | JAK2 Inhibitors RUXOLITINIB in Patients With Myelofibrosis |
| Q63581579 | Jaktinib Dihydrochloride Monohydrate in Intermediate-risk and High-risk Myelofibrosis. |
| Q83794878 | Jaktinib Hydrochloride for the Treatment of Ruxolitinib Intolerance of Myelofibrosis |
| Q62062253 | KRT-232 in Subjects With PMF, Post-PV MF, or Post-ET MF Who Have Failed a JAK Inhibitor |
| Q63338573 | LBH589 (Panobinostat) for the Treatment of Myelofibrosis |
| Q65542986 | Lenalidomide and Prednisone in Treating Patients With Myelofibrosis |
| Q65387594 | Lenalidomide for Patients With Myelofibrosis (MF) |
| Q65472845 | Lithium Carbonate in Treating Patients With Acute Intestinal Graft-Versus-Host-Disease (GVHD) After Donor Stem Cell Transplant |
| Q66403132 | Long-Term Side Effects of Ruxolitinib in Treating Patients With Myelofibrosis |
| Q65360090 | Long-term Safety and Efficacy of Momelotinib in Subjects With Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis, Polycythemia Vera or Essential Thrombocythemia |
| Q65378336 | Low-Dose Decitabine in Treating Patients With Symptomatic Myelofibrosis |
| Q63580663 | MPN-RC 118 AVID200 in Myelofibrosis |
| Q66043141 | Management of Platelet Transfusion Therapy in Patients With Blood Cancer or Treatment-Induced Thrombocytopenia |
| Q64657023 | Massage Therapy Given by Caregiver in Treating Quality of Life of Young Patients Undergoing Treatment for Cancer |
| Q65374491 | Mechanical Stimulation in Preventing Bone Density Loss in Patients Undergoing Donor Stem Cell Transplant |
| Q65383819 | Molecular Changes and Biomarkers in Chronic Myeloproliferative Disorders |
| Q61975403 | Momelotinib Versus Ruxolitinib in Subjects With Myelofibrosis |
| Q65342084 | Momelotinib in Transfusion-Dependent Adults With Primary Myelofibrosis (PMF) or Post-polycythemia Vera or Post-essential Thrombocythemia Myelofibrosis (Post-PV/ET MF) |
| Q63807912 | Multi-antigen CMV-MVA Triplex Vaccine in Reducing CMV Complications in Patients Previously Infected With CMV and Undergoing Donor Hematopoietic Cell Transplant |
| Q63401564 | Multi-antigen CMV-Modified Vaccinia Ankara Vaccine in Reducing CMV Related Complications in Patients With Blood Cancer Undergoing Donor Stem Cell Transplant |
| Q63570845 | Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders |
| Q65473725 | Myeloablative Umbilical Cord Blood Transplantation in Hematological Diseases |
| Q62025798 | Myelofibrosis Treated With Pacritinib Before aSCT. (HOVON134MF) |
| Q63571073 | Myelofibrosis and Essential Thrombocythemia Observational Study (MOST) |
| Q66080324 | Myeloid-Derived Suppressor Cells and Checkpoint Immune Regulators' Expression in Allogeneic SCT Using FluBuATG |
| Q66404625 | Myeloproliferative Neoplasms (MPNs) Patient Registry |
| Q64625649 | Myeloproliferative Neoplasms and Bone Structure |
| Q65368471 | Myeloproliferative Neoplasms: an In-depth Case-control Study |
| Q66082684 | Myeloproliferative Neoplastic Diseases Observatory From Brest |
| Q64140171 | Nivolumab in Treating Patients With Primary Myelofibrosis, Post-Essential Thrombocythemia Myelofibrosis, or Post-Polycythemia Vera Myelofibrosis |
| Q65354847 | Nonmyeloablative Hematopoietic Cell Transplantation (HCT) for Patients With Hematologic Malignancies Using Related, HLA-Haploidentical Donors: A Pilot Trial of Peripheral Blood Stem Cells (PBSC) as the Donor Source |
| Q64709464 | Ondansetron in Preventing Nausea and Vomiting in Patients Undergoing Stem Cell Transplant |
| Q61979326 | Open Label Ruxolitinib (INCB018424) in Patients With Myelofibrosis and Post Polycythemia Vera/Essential Thrombocythemia Myelofibrosis |
| Q66346015 | Oral Pacritinib Versus Best Available Therapy to Treat Myelofibrosis |
| Q64336392 | Oral Pacritinib Versus Best Available Therapy to Treat Myelofibrosis With Thrombocytopenia |
| Q67128880 | P1101 in Treating Patients With Myelofibrosis |
| Q67124391 | PAT-1251 in Treating Patients With Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocytosis Myelofibrosis |
| Q63229537 | PD-1 Inhibition in Advanced Myeloproliferative Neoplasms |
| Q66399964 | PK of Pacritinib in Patients With Mild, Moderate, Severe Renal Impairment and ESRD Compared to Healthy Subjects |
| Q66400130 | PTCy and Ruxolitinib GVHD Prophylaxis in Myelofibrosis |
| Q62110265 | PTK 787 and Gleevec in Patients With AML, AMM, and CML-BP |
| Q67125672 | Pacritinib in Combination With Low Dose Decitabine in Intermediate-High Risk Myelofibrosis or Myeloproliferative Neoplasm (MPN)/Myelodysplastic Syndrome (MDS) |
| Q63340876 | Palifermin in Preventing Chronic Graft-Versus-Host Disease in Patients Who Have Undergone Donor Stem Cell Transplant for Hematologic Cancer |
| Q64640684 | Panobinostat and Ruxolitinib In MyElofibrosis (PRIME Trial) |
| Q64648120 | Panobinostat and Ruxolitinib in Primary Myelofibrosis, Post-polycythemia Vera-myelofibrosis or Post-essential Thrombocythemia-myelofibrosis |
| Q63837586 | Pegylated Interferon Alpha-2b in Early Primary Myelofibrosis |
| Q61921619 | Pemetrexed Disodium in the Cerebrospinal Fluid of Patients With Leptomeningeal Metastases |
| Q63811793 | Pevonedistat in Combination With Ruxolitinib for Treatment of Patients With Myelofibrosis |
| Q65469926 | Ph II Study of Azacitidine in Myelofibrosis |
| Q64151865 | Phase 2 LCL-161 in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (Post-PV MF) or Post-Essential Thrombocytosis Myelofibrosis (Post-ET MF) |
| Q64640825 | Phase 2 Study in Japanese Patients With Intermediate-2 or High Risk Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, Post-Essential Thrombocythemia Myelofibrosis With Splenomegaly |
| Q63322219 | Phase 2 Study of SAR302503 in Patients With Myelofibrosis |
| Q63807534 | Phase I Clinical Study of CWP232291 in Acute Myeloid Leukemia Patients |
| Q64679858 | Phase I Dose-Escalation Trial of Clofarabine Followed by Escalating Doses of Fractionated Cyclophosphamide in Children With Relapsed or Refractory Acute Leukemias |
| Q64048453 | Phase II Study of Bevacizumab (Avastin®) in Myelofibrosis |
| Q63319645 | Phase II, Open Label, Single Arm Study of SAR302503 In Myelofibrosis Patients Previously Treated With Ruxolitinib |
| Q64216571 | Phase III Study Investigating the Efficacy and Safety of Ruxolitinib in Early Myelofibrosis Patients With High Molecular Risk Mutations. |
| Q64647795 | Phase III Study of SAR302503 in Intermediate-2 and High Risk Patients With Myelofibrosis |
| Q87930562 | Phase Ib Multicenter, Open-label Escalation/Expansion Platform Study of Select Combinations in Adults With Myelofibrosis |
| Q63829461 | Phase-3 Double-Blind, Placebo-Controlled Study of Pomalidomide in Persons With Myeloproliferative-Neoplasm-Associated Myelofibrosis and RBC-Transfusion-Dependence Myelofibrosis and RBC-Transfusion-Dependence |
| Q64791260 | Pilot Study for the Development of a Diagnostic Score to Differentiate Myeloproliferative Neoplasms. |
| Q65378673 | Pilot Trial of Arsenic + Cytarabine in Patients With Myelofibrosis |
| Q74283076 | Platform Study of Novel Ruxolitinib Combinations in Myelofibrosis Patients |
| Q64718763 | Polycythemia Vera, Myelofibrosis and Essential Thrombocythemia: Identification of PV, MF & ET Genes |
| Q64665376 | Pomalidomide for Myelofibrosis Patients |
| Q64223115 | Post Transplant Cyclophosphamide (Cytoxan) for GvHD Prophylaxis |
| Q64647122 | Prolonged or Standard Infusion of Cefepime Hydrochloride in Treating Patients With Febrile Neutropenia |
| Q66080410 | Prospective Assessment of Allogeneic Hematopoietic Cell Transplantation in Patients With Myelofibrosis |
| Q61975083 | Quantitative MRI for Myelofibrosis |
| Q66033611 | RAD001 in Relapsed or Refractory AML, ALL, CML in Blastic-Phase, Agnogenic Myeloid Metaplasia, CLL, T-Cell Leukemia, or Mantle Cell Lymphoma |
| Q65316135 | RIC Transplant Using Haplo Donors |
| Q64693170 | Reduced Intensity Allogeneic PBSCT to Treat Hematologic Malignancies and Hematopoietic Failure States |
| Q93214922 | Reduced Intensity Haploidentical Transplantation for the Treatment of Primary or Secondary Myelofibrosis |
| Q63836792 | Reduced-Intensity Conditioning Before Donor Stem Cell Transplant in Treating Patients With High-Risk Hematologic Malignancies |
| Q64048601 | Research Tissue Bank |
| Q64717283 | Reversible Secondary Myelofibrosis or Clonal Myeloproliferative Disorder |
| Q63335474 | Ruxolitinib (INCB018424) in Subjects With Primary Myelofibrosis, Post Essential Thrombocythemia-myelofibrosis and Post Polycythemia Vera-myelofibrosis |
| Q64150502 | Ruxolitinib Phosphate and Azacytidine in Treating Patients With Myelofibrosis or Myelodysplastic Syndrome/Myeloproliferative Neoplasm |
| Q64172192 | Ruxolitinib Phosphate and Chemotherapy Given Before and After Reduced Intensity Donor Stem Cell Transplant in Treating Patients With Myelofibrosis |
| Q64637528 | Ruxolitinib Phosphate and Danazol in Treating Anemia in Patients With Myelofibrosis |
| Q65335713 | Ruxolitinib Phosphate, Tacrolimus and Sirolimus in Preventing Acute Graft-versus-Host Disease During Reduced Intensity Donor Hematopoietic Cell Transplant in Patients With Myelofibrosis |
| Q63401143 | Ruxolitinib Pre-, During- and Post-HSCT for Patients With Primary or Secondary Myelofibrosis. |
| Q64635254 | Ruxolitinib Prior to Transplant in Patients With Myelofibrosis |
| Q63812726 | Ruxolitinib and Lenalidomide for Patients With Myelofibrosis |
| Q64030344 | Ruxolitinib and Pomalidomide Combination Therapy in Patients With Primary and Secondary MF |
| Q64600460 | Ruxolitinib and Pracinostat Combination Therapy for Patients With Myelofibrosis (MF) |
| Q94234656 | Ruxolitinib for the Treatment of Graft Versus Host Disease Following Stem Cell Transplant in Patients With Primary and Secondary Myelofibrosis |
| Q65346378 | Ruxolitinib in Combination With Autotransplant |
| Q64151213 | Ruxolitinib in Myelofibrosis Patients in Lombardy, Italy |
| Q64790149 | Ruxolitinib vs Allogeneic SCT for Patients With Myelofibrosis According to Donor Availability |
| Q64600277 | SL-401 in Advanced, High Risk Myeloproliferative Neoplasms (Systemic Mastocytosis, Advanced Symptomatic Primary Eosinophilic Disorder, Myelofibrosis, Chronic Myelomonocytic Leukemia) |
| Q63321780 | Safety Study Evaluating Twice-Daily Administration of Momelotinib in Primary Myelofibrosis or Post-Polycythemia Vera or Post-Essential Thrombocythemia Myelofibrosis |
| Q64673294 | Safety and Efficacy Study of CYT387 in Primary Myelofibrosis (PMF) or Post-polycythemia Vera (PV) or Post-essential Thrombocythemia (ET) |
| Q65474701 | Safety and Efficacy of Obatoclax Mesylate (GX15-070MS) in the Treatment of Myelofibrosis With Myeloid Metaplasia |
| Q64673642 | Safety and Efficacy of Panobinostat in Patients With Primary Myelofibrosis |
| Q86276762 | Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis |
| Q105493975 | Safety and Tolerability Study of Mivebresib Tablet Alone or in Combination With Ruxolitinib Tablet or Navitoclax Tablet in Adult Participants With Myelofibrosis |
| Q97461336 | Safety and Tolerability Study of Oral ABBV-744 Tablet Alone or in Combination With Oral Ruxolitinib Tablet or Oral Navitoclax Tablet in Adult Participants With Myelofibrosis |
| Q63321625 | Safety and Tolerability Study of Oral NS-018 in Patients With Primary Myelofibrosis (MF), Post-polycythemia Vera MF or Post-essential Thrombocythemia MF |
| Q102153670 | Safety, Efficacy, and Assessment of Change in Spleen Volume Study of Oral Navitoclax Tablet in Combination With Oral Ruxolitinib Tablet in Adult Participants With Relapsed/Refractory Myelofibrosis |
| Q64375335 | Safety, Tolerability, and Pharmacokinetics of Idelalisib in Adults Receiving Ruxolitinib as Therapy for Primary, Post-Polycythemia Vera, or Post-Essential Thrombocythemia Myelofibrosis With Progressive or Relapsed Disease |
| Q64170774 | Screening for Asymptomatic Portal Vein Thrombosis and Portal Hypertension in Patients With Philadelphia Negative Myeloproliferative Neoplasms |
| Q62034506 | Secondary Cancers in Myeloproliferative Neoplasms (MPN-K Study) |
| Q63393521 | Selinexor in Myelofibrosis Refractory or Intolerant to JAK1/2 Inhibitors |
| Q65329759 | Shorter Course Tacro After NMA, Related Donor PBSCT With High-dose Posttransplant Cy for Hard-to-Engraft Malignancies |
| Q65472088 | Sibling Donor Peripheral Stem Cell Transplant or Sibling Donor Bone Marrow Transplant in Treating Patients With Hematologic Cancers or Other Diseases |
| Q66400247 | Siltuximab in Treating Patients With Primary, Post-Polycythemia Vera, or Post-Essential Thrombocythemia Myelofibrosis |
| Q64606807 | Single-Agent Glasdegib In Patients With Myelofibrosis Previously Treated With Ruxolitinib |
| Q66546799 | Single-Arm Study of the Efficacy and Safety of Oral Rigosertib in Patients With Myelofibrosis (MF) and Anemia |
| Q66546994 | Sirolimus and Mycophenolate Mofetil in Preventing GVHD in Patients With Hematologic Malignancies Undergoing HSCT |
| Q64725514 | Sirolimus, Tacrolimus, and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant For Hematological Cancer |
| Q62110554 | Study of AP23573 in Patients With Relapsed or Refractory Hematologic Malignancies (8669-024)(COMPLETED) |
| Q64726073 | Study of Fludarabine Based Conditioning for Allogeneic Stem Cell Transplantation for Myelofibrosis |
| Q63829888 | Study of Hypoxia-Activated Prodrug TH-302 to Treat Advanced Leukemias |
| Q63819191 | Study of KB004 in Subjects With Hematologic Malignancies (Myelodysplastic Syndrome, MDS, Myelofibrosis, MF) |
| Q63320463 | Study of LY2784544 Testing Alternative Dosing in Participants With Myeloproliferative Neoplasms |
| Q63534287 | Study of MEK Inhibitor Selumetinib in Combination With Azacitidine in Patients With Higher Risk Chronic Myeloid Neoplasia |
| Q105088861 | Study of Oral Navitoclax Tablet In Combination With Oral Ruxolitinib Tablet When Compared With Oral Ruxolitinib Tablet To Assess Change In Spleen Volume In Adult Participants With Myelofibrosis |
| Q65386351 | Study of Parathyroid Hormone Following Sequential Cord Blood Transplantation From an Unrelated Donor |
| Q63338170 | Study of Ruxolitinib (INCB018424) Sustained Release Formulation in Myelofibrosis Patients |
| Q64653331 | Study of SB939 in Subjects With Myelofibrosis |
| Q64187161 | Study of Sotatercept (ACE-011) in Subjects With Myeloproliferative Neoplasm (MPN)-Associated Myelofibrosis (MF) and Anemia |
| Q83794352 | Study of Stem Cell Transplant vs. Non-Transplant Therapies in High-Risk Myelofibrosis |
| Q63337559 | Study of the JAK Inhibitor Ruxolitinib Administered Orally to Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera-Myelofibrosis (PPV-MF) or Post-Essential Thrombocythemia-Myelofibrosis (PET-MF) |
| Q64188436 | Study of the Safety of PIM447 in Combination With Ruxolitinib (INC424) and LEE011 in Patients With Myelofibrosis |
| Q64675357 | Study to Assess the Safety of AZD1480 in Patients With Myeloproliferative Diseases |
| Q65382272 | Study to Assess the Safety of Escalating Doses of AT9283, in Patients With Leukemias |
| Q64625872 | Study to Compare Busulfan-fludarabine With Thiotepa-fludarabine Regimen in Allogeneic Transplantation for Myelofibrosis |
| Q64395181 | Study to Evaluate Activity of 2 Dose Levels of Imetelstat in Participants With Intermediate-2 or High-Risk Myelofibrosis (MF) Previously Treated With Janus Kinase (JAK) Inhibitor |
| Q105088324 | Study to Evaluate Safety, Pharmacokinetic and Pharmacodynamic Dose Escalation and Expansion Study of PXS-5505 in Patients With Primary, Post-polycythemia Vera or Post-essential Thrombocythemia Myelofibrosis |
| Q64678107 | Sunitinib Malate in Treating HIV-Positive Patients With Cancer Receiving Antiretroviral Therapy |
| Q65474517 | Sunitinib in Treating Patients With Idiopathic Myelofibrosis |
| Q87932847 | Survival in Myelofibrosis Patients After Allogeneic Hematopoietic Stem Cell Transplantation in Five Centers in France |
| Q64140189 | Sympathicomimetic Agonist in Patients With Myeloproliferative Neoplasms With JAK2-mutation |
| Q64725510 | T-Cell Depletion, Donor Hematopoietic Stem Cell Transplant (HSCT), and T-Cell Infusions in Treating Patients With Hematologic Cancer or Other Diseases |
| Q65345283 | TGR-1202 + Ruxolitinib PMF PPV-MF PET-MF MDS/MPN Polycythemia Vera Resistant to Hydroxyurea |
| Q63338132 | TXA127 in Enhancement of Engraftment in Adult Double Cord Blood Transplantation |
| Q62110098 | Tacrolimus and Mycophenolate Mofetil in Preventing Graft-Versus-Host Disease in Patients Who Have Undergone Total-Body Irradiation With or Without Fludarabine Phosphate Followed by Donor Peripheral Blood Stem Cell Transplant for Hematologic Cancer |
| Q66083050 | Tacrolimus, Bortezomib, & Thymoglobulin in Preventing Low Toxicity GVHD in Donor Blood Stem Cell Transplant Patients |
| Q65359555 | Targeted Marrow Irradiation, Fludarabine Phosphate, and Busulfan Before Donor Progenitor Cell Transplant in Treating Patients With Hematologic Malignancies |
| Q66036246 | Thalidomide in Treating Patients With Myelofibrosis |
| Q61924492 | Thalidomide, Prednisone, and Cyclophosphamide in Treating Patients With Myelofibrosis and Myeloid Metaplasia |
| Q63587655 | The NUTRIENT Trial (NUTRitional Intervention Among myEloproliferative Neoplasms): Feasibility Phase |
| Q65387355 | Thymoglobuline Versus Alemtuzumab in Patients Undergoing Allogeneic Transplant |
| Q66037782 | Tipifarnib in Treating Patients With Myelofibrosis and Myeloid Metaplasia |
| Q106637637 | To Assess the Safety, Tolerability and Efficacy of Itacitinib Immediate Release Tablets in Participants With Primary or Secondary Myelofibrosis Who Have Received Prior Ruxolitinib and/or Fedratinib Monotherapy. (LIMBER-213) |
| Q106637656 | To Evaluate Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis Who Have Suboptimal Response to Ruxolitinib (LIMBER-304) (2021-03-31) |
| Q106975759 | To Evaluate Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis Who Have Suboptimal Response to Ruxolitinib (LIMBER-304) (2021-06-30) |
| Q106637655 | To Evaluate the Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis (LIMBER-313) (2021-03-31) |
| Q64189603 | Topotecan Hydrochloride and Carboplatin With or Without Veliparib in Treating Advanced Myeloproliferative Disorders and Acute Myeloid Leukemia or Chronic Myelomonocytic Leukemia |
| Q64725025 | Total Body Irradiation With Fludarabine Followed by Combined Umbilical Cord Blood (UCB) Transplants |
| Q63817202 | Traditional Chinese Medicine in the Supportive Management of Anaemic and Cytopenic (Leukopenia, Thrombocytopenia) Haematological Disorders |
| Q63578023 | Trial Ruxolitinib and Peg-interferon Alpha-2a Combination in Patients With Primary Myelofibrosis RUXOPeg |
| Q67128102 | Triplex Vaccine in Preventing CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplantation |
| Q66406711 | UCB Transplant for Hematological Diseases Using a Non Myeloablative Prep |
| Q65466054 | URMC Related Haplo-identical Donor BMT |
| Q61921654 | Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic Cancer or Other Disease |
| Q74131654 | Umbilical Cord Blood T-Regulatory Cell Infusion Followed by Donor Umbilical Cord Blood Transplant in Treating Patients With High-Risk Leukemia or Other Hematologic Diseases |
| Q64121051 | Umbilical Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With Hematologic Disease |
| Q64352944 | Umbilical Cord Blood Transplantation Using a Myeloablative Preparative Regimen for Hematological Diseases |
| Q63844345 | Vaccine Therapy in Preventing Cytomegalovirus Infection in Patients With Hematological Malignancies Undergoing Donor Stem Cell Transplant |
| Q67128617 | Vaccine Therapy in Reducing the Frequency of Cytomegalovirus Events in Patients With Hematologic Malignancies Undergoing Donor Stem Cell Transplant |
| Q65475258 | Vorinostat, Cytarabine, and Etoposide in Treating Patients With Relapsed and/or Refractory Acute Leukemia or Myelodysplastic Syndromes or Myeloproliferative Disorders |
| Q64123248 | iCare for Cancer Patients |
| Q39029265 | 'JAK-ing' up the treatment of primary myelofibrosis: building better combination strategies |
| Q33494033 | 1 alpha-Hydroxyvitamin D3 in the treatment of primary myelofibrosis: in vitro effect of vitamin D3 metabolites on the bone marrow fibroblasts. |
| Q90273959 | 20+ Years and alive with primary myelofibrosis: Phenotypic signature of very long-lived patients |
| Q97532867 | A Case of Acquired Gray Platelet Syndrome Associated with Primary Myelofibrosis |
| Q94549896 | A Case of Primary Myelofibrosis in Which Ruxolitinib Therapy Ameliorated the Fibrosis, but Resulted in Fatty Marrow |
| Q99628490 | A Mildly Symptomatic Middle-Aged Woman with INT-1 Primary Myelofibrosis |
| Q90936393 | A Rare Case of Primary Myelofibrosis With a Solitary 1q Triplication |
| Q40616947 | A Rare Case of Primary Myelofibrosis in a 14-Year-Old Patient With Congenital Asplenia |
| Q61801129 | A Rare Case of Spontaneous Tumor Lysis Syndrome in Idiopathic Primary Myelofibrosis |
| Q36916130 | A case of Philadelphia chromosome positive myeloproliferative neoplasm in a pregnant woman with unusual primary myelofibrosis features |
| Q81249216 | A case of Philadelphia-chromosome positive chronic idiopathic myelofibrosis |
| Q67723343 | A case of primary myelofibrosis associated with massive splenomegaly (author's transl) |
| Q70594209 | A case of primary myelofibrosis complicated with cardiac tamponade |
| Q72390475 | A case of primary myelofibrosis terminating in acute megakaryoblastic leukemia: identification by the demonstration of platelet peroxidase |
| Q31110460 | A data-driven network model of primary myelofibrosis: transcriptional and post-transcriptional alterations in CD34+ cells. |
| Q90273548 | A distinct molecular mutational profile and its clinical impact in essential thrombocythemia and primary myelofibrosis patients |
| Q61050093 | A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment). |
| Q58010175 | A higher JAK2 V617F-mutated clone is observed in platelets than in granulocytes from essential thrombocythemia patients, but not in patients with polycythemia vera and primary myelofibrosis |
| Q84528407 | A novel cytogenetic abnormality in primary myelofibrosis |
| Q83258186 | A novel immunohistochemical sequential multi-labelling and erasing technique enables epitope characterization of bone marrow pericytes in primary myelofibrosis |
| Q47766453 | A phase 1 study of the Janus kinase 2 (JAK2)V617F inhibitor, gandotinib (LY2784544), in patients with primary myelofibrosis, polycythemia vera, and essential thrombocythemia |
| Q64040647 | A phase 2 trial of combination therapy with thalidomide, arsenic trioxide, dexamethasone, and ascorbic acid (TADA) in patients with overlap myelodysplastic/myeloproliferative neoplasms (MDS/MPN) or primary myelofibrosis (PMF) |
| Q33405372 | A phase I study of panobinostat (LBH589) in patients with primary myelofibrosis (PMF) and post-polycythaemia vera/essential thrombocythaemia myelofibrosis (post-PV/ET MF). |
| Q91511764 | A phase I study of panobinostat and ruxolitinib in patients with primary myelofibrosis (PMF) and post--polycythemia vera/essential thrombocythemia myelofibrosis (post--PV/ET MF) |
| Q51279169 | A phase II study of panobinostat in patients with primary myelofibrosis (PMF) and post-polycythemia vera/essential thrombocythemia myelofibrosis (post-PV/ET MF). |
| Q42551329 | A phase II study of vorinostat (MK-0683) in patients with primary myelofibrosis and post-polycythemia vera myelofibrosis |
| Q66863263 | A preliminary study on humoral control of granulopoiesis in primary myelofibrosis and chronic granulocytic leukaemia |
| Q94472419 | A provider's guide to primary myelofibrosis: pathophysiology, diagnosis, and management |
| Q101408301 | A study of 18F-FLT positron emission tomography/computed tomography imaging in cases of prefibrotic/early primary myelofibrosis and essential thrombocythemia |
| Q64086017 | A systematic review and meta-analysis of the prevalence of thrombosis and bleeding at diagnosis of Philadelphia-negative myeloproliferative neoplasms |
| Q43237567 | A unified definition of clinical resistance and intolerance to hydroxycarbamide in polycythaemia vera and primary myelofibrosis: results of a European LeukemiaNet (ELN) consensus process |
| Q36771352 | A3669G polymorphism of glucocorticoid receptor is a susceptibility allele for primary myelofibrosis and contributes to phenotypic diversity and blast transformation |
| Q100525829 | ASXL1 mutation confers poor prognosis in primary myelofibrosis patients with low JAK2V617F allele burden but not in those with high allele burden |
| Q44538665 | Abdominal mass and pyrexia: (primary myelofibrosis and ileus--adhesion of the jejunum and spleen) |
| Q35607194 | Aberrant collagenase expression in chronic idiopathic myelofibrosis is related to the stage of disease but not to the JAK2 mutation status |
| Q82606311 | Aberrant myeloid maturation identified by flow cytometry in primary myelofibrosis |
| Q54214351 | Abnormal expression patterns of WT1-as, MEG3 and ANRIL long non-coding RNAs in CD34+ cells from patients with primary myelofibrosis and their clinical correlations. |
| Q99574811 | Abnormally short erythrocyte lifespan in three patients with primary myelofibrosis despite successful control of splenomegaly |
| Q68000179 | About primary myelofibrosis |
| Q82300298 | Acquired Hb H disease associated with elevated Hb F level in patient affected by primary myelofibrosis |
| Q82660944 | Acquired resistance to interferon alpha therapy associated with homozygous MPL-W515L mutation and chromosome 20q deletion in primary myelofibrosis |
| Q56529658 | Acral Hyperpigmentation Resulting from Hydroxyurea Therapy in Primary Myelofibrosis |
| Q35113804 | Activation of non-canonical TGF-β1 signaling indicates an autoimmune mechanism for bone marrow fibrosis in primary myelofibrosis |
| Q38041128 | Acute Myeloid Leukemia Evolving from JAK 2-Positive Primary Myelofibrosis and Concomitant CD5-Negative Mantle Cell Lymphoma: A Case Report and Review of the Literature |
| Q35998037 | Acute lymphoblastic leukemic transformation in a patient with chronic idiopathic myelofibrosis and paroxysmal nocturnal hemoglobinuria: a case report and review of the literature |
| Q33416494 | Acute respiratory distress syndrome in a patient with primary myelofibrosis after ruxolitinib treatment discontinuation |
| Q93248149 | Acute variceal bleeding in patients with primary myelofibrosis successfully treated with endoscopic histoacryl injection |
| Q91956190 | Adhesion to Fibronectin via α5β1 Integrin Supports Expansion of Megakaryocyte Lineage in Primary Myelofibrosis |
| Q36584994 | Advances in the therapy of chronic idiopathic myelofibrosis |
| Q53184342 | Age and platelet count are IPSS-independent prognostic factors in young patients with primary myelofibrosis and complement IPSS in predicting very long or very short survival. |
| Q83954997 | Allele-specific wild-type blocker quantitative PCR for highly sensitive detection of rare JAK2 p.V617F point mutation in primary myelofibrosis as an appropriate tool for the monitoring of molecular remission following therapy |
| Q33197751 | Allogeneic bone marrow transplantation for primary myelofibrosis |
| Q69424328 | Allogeneic bone marrow transplantation for primary myelofibrosis |
| Q69485405 | Allogeneic bone marrow transplantation for primary myelofibrosis |
| Q71375633 | Allogeneic bone marrow transplantation for primary myelofibrosis |
| Q38337632 | Allogeneic haematopoietic stem cell transplantation for primary myelofibrosis and myelofibrosis evolved from other myeloproliferative neoplasms |
| Q47174502 | Allogeneic hemopoietic SCT for patients with primary myelofibrosis: a predictive transplant score based on transfusion requirement, spleen size and donor type |
| Q73774686 | Allogeneic marrow transplantation for primary myelofibrosis and myelofibrosis secondary to polycythaemia vera or essential thrombocytosis |
| Q38285259 | Allogeneic stem cell transplant vs.Janus kinase inhibition in the treatment of primary myelofibrosis or myelofibrosis after essential thrombocythemia or polycythemia vera |
| Q33556843 | Allogeneic transplantation for primary myelofibrosis with BM, peripheral blood or umbilical cord blood: an analysis of the JSHCT |
| Q69236094 | Alpha interferon in primary myelofibrosis |
| Q37353939 | Altered SDF-1/CXCR4 axis in patients with primary myelofibrosis and in the Gata1 low mouse model of the disease |
| Q53581784 | An Autopsy Case of Primary Myelofibrosis with Skin Tumors Terminating in Leukemic Transformation (author's transl) |
| Q44889444 | An autopsied case of primary myelofibrosis with blastic proliferation terminating in ileus (author's transl) |
| Q53588702 | An autopsy case of primary myelofibrosis terminating in leukemic transformation (author's transl) |
| Q40955709 | An unusual long-term outcome of a child with primary myelofibrosis harboring a JAK2 mutation |
| Q89203608 | An unusual presentation of primary myelofibrosis |
| Q88117216 | An unusual, activating insertion/deletion MPL mutant in primary myelofibrosis |
| Q64067556 | Analysis of genes encoding epigenetic regulators in myeloproliferative neoplasms: Coexistence of a novel mutation in a patient with a p.V617F positive myelofibrosis |
| Q80128477 | Analysis of risk factors of the evolution of myelofibrosis in pre-fibrotic chronic idiopathic myelofibrosis: a retrospective study based on follow up biopsies of 70 patients by using the RECPAM method |
| Q88322784 | Anisocytosis: A Classical Marker of Inflammation or a New Predictive Marker in Patients with Primary Myelofibrosis |
| Q54509780 | Application of an NGS-based 28-gene panel in myeloproliferative neoplasms reveals distinct mutation patterns in essential thrombocythaemia, primary myelofibrosis and polycythaemia vera. |
| Q47147199 | Application of current prognostic models for primary myelofibrosis in the setting of post-polycythemia vera or post-essential thrombocythemia myelofibrosis |
| Q44300500 | Application of five prognostic survival scores to primary myelofibrosis in 62 Brazilian patients. |
| Q41368361 | Assessment of sites of marrow and extramedullary hematopoiesis by hybrid imaging in primary myelofibrosis patients |
| Q52813540 | Austrian recommendations for the management of primary myelofibrosis, post-polycythemia vera myelofibrosis and post-essential thrombocythemia myelofibrosis: an expert statement. |
| Q67808308 | Auto-immunity in primary myelofibrosis |
| Q44241866 | Autoimmunity and deficiency of cell-mediated immunity in primary myelofibrosis |
| Q54509748 | Autopsy case of primary myelofibrosis in which myeloid sarcoma was the initial manifestation of tumor progression. |
| Q33388685 | Beneficial treatment with methyl 6-[3-(2-chloroethyl)-3-nitrosoureido]-6-deoxy-alpha-D-glucopyranoside in a patient with primary myelofibrosis |
| Q88527527 | Bilateral adrenal hemorrhage as a manifestation of extramedullary hematopoiesis in a patient with primary myelofibrosis |
| Q42857556 | Bilateral ureteral obstruction due to primary myelofibrosis caused hyperuricaemia |
| Q79777312 | Blood film features of primary myelofibrosis |
| Q51452739 | Blood tests may predict early primary myelofibrosis in patients presenting with essential thrombocythemia. |
| Q72033216 | Bone and bone-marrow blood flow in chronic granulocytic leukemia and primary myelofibrosis |
| Q26745943 | Bone marrow fibrosis in primary myelofibrosis: pathogenic mechanisms and the role of TGF-β |
| Q44667837 | Bone marrow histopathology following cytoreductive therapy in chronic idiopathic myelofibrosis |
| Q43687433 | Bone marrow histopathology in primary myelofibrosis: clinical and haematologic correlations and prognostic evaluation |
| Q63633939 | Bone marrow trephine biopsy findings in primary myelofibrosis |
| Q36512309 | Bone morphogenetic proteins are overexpressed in the bone marrow of primary myelofibrosis and are apparently induced by fibrogenic cytokines |
| Q27852820 | CALR and ASXL1 mutations-based molecular prognostication in primary myelofibrosis: an international study of 570 patients |
| Q61758700 | CALR exon 9 mutations are somatically acquired events in familial cases of essential thrombocythemia or primary myelofibrosis |
| Q53224139 | CALR, JAK2, and MPL mutation profiles in patients with four different subtypes of myeloproliferative neoplasms: primary myelofibrosis, essential thrombocythemia, polycythemia vera, and myeloproliferative neoplasm, unclassifiable. |
| Q51434828 | CALR-mutated primary myelofibrosis evolving to chronic myeloid leukemia with both CALR mutation and BCR-ABL1 fusion gene. |
| Q35669866 | CD133 marks a stem cell population that drives human primary myelofibrosis |
| Q24649607 | CD146(+) bone marrow osteoprogenitors increase in the advanced stages of primary myelofibrosis |
| Q77802690 | CD34+ progenitor cells in idiopathic (primary) myelofibrosis: a comparative quantification between spleen and bone marrow tissue |
| Q99730667 | CYTOGENETIC STUDY IN PRIMARY MYELOFIBROSIS AT DIAGNOSIS: CLINICAL AND HISTOLOGICAL ASSOCIATION AND IMPACT ON SURVIVAL ACCORDING TO WHO 2017 CLASSIFICATION IN AN ITALIAN MULTICENTER SERIES |
| Q34463652 | Calreticulin mutations in Chinese with primary myelofibrosis |
| Q85850954 | Case 2-2012: a 57-year-old woman with post-transplant lymphoproliferative disorder after allogeneic stem cell transplantation for primary myelofibrosis |
| Q33551185 | Case of bilateral retinal neovascularization associated with chronic idiopathic myelofibrosis |
| Q72384780 | Case of primary myelofibrosis |
| Q38623991 | Cementless Total Hip Arthroplasty in Primary Myelofibrosis - a Case Report |
| Q68274299 | Characteristics of circulating megakaryocyte progenitors (CFU-MK) in patients with primary myelofibrosis |
| Q57821984 | Characterization of a human induced Pluripotent Stem (iPS) cell line (INCABRi002-A) derived from a primary myelofibrosis patient harboring the 5-bp insertion in CALR and the p.W146X mutation in TP53 |
| Q93113349 | Chromosome 12 Rearrangement in an Adolescent with Primary Myelofibrosis |
| Q41233538 | Chronic Idiopathic Myelofibrosis. A Reversible Disease? |
| Q53600678 | Chronic idiopathic myelofibrosis (CIMF) resulting from a unique 3;9 translocation disrupting the janus kinase 2 (JAK2) gene. |
| Q79378536 | Chronic idiopathic myelofibrosis expressing a novel type of TEL-PDGFRB chimaera responded to imatinib mesylate therapy |
| Q37223079 | Chronic idiopathic myelofibrosis presenting as cauda equina compression due to extramedullary hematopoiesis: a case report |
| Q54628962 | Chronic idiopathic myelofibrosis terminating in extramedullary anaplastic plasmacytoma. |
| Q43270375 | Chronic idiopathic myelofibrosis with myeloid metaplasia presenting as refractory ascites |
| Q33252344 | Chronic idiopathic myelofibrosis: clinicopathologic features, pathogenesis, and prognosis |
| Q80375976 | Chronic idiopathic myelofibrosis: independent prognostic importance of bone marrow microvascular density evaluated by CD105 (endoglin) immunostaining |
| Q79177537 | Chronic idiopathic myelofibrosis: prognostic impact of myelofibrosis and clinical parameters on event-free survival in 122 patients who presented in prefibrotic and fibrotic stages. A retrospective study identifying subgroups of different prognoses |
| Q81398465 | Chronic megakaryocytic leukemia, misnamed chronic idiopathic myelofibrosis, has neoplastic not hyperplastic megakaryocytopoiesis |
| Q86883507 | Chronic myeloid leukaemia masquerading as primary myelofibrosis |
| Q51539536 | Circulating Cd34+ cell count differentiates primary myelofibrosis from other Philadelphia-negative myeloproliferative neoplasms: a pragmatic study. |
| Q87547449 | Circulating hematopoietic progenitor cells in essential thrombocythemia versus prefibrotic/early primary myelofibrosis |
| Q33394025 | Circulating interleukin (IL)-8, IL-2R, IL-12, and IL-15 levels are independently prognostic in primary myelofibrosis: a comprehensive cytokine profiling study |
| Q98228539 | Classical Hodgkin lymphoma-like post-transplant lymphoproliferative disease after allogeneic stem cell transplantation for primary myelofibrosis is successfully treated with nivolumab: A case report |
| Q93053751 | Clinical and molecular features of patients with prefibrotic primary myelofibrosis previously diagnosed as having essential thrombocythemia in Japan |
| Q93564038 | Clinical and pathological features of primary myelofibrosis from onset to blast transformation: report of two cases |
| Q38200479 | Clinical aspects of primary myelofibrosis in Japan |
| Q66983449 | Clinical characteristics of primary myelofibrosis |
| Q33416223 | Clinical effect of driver mutations of JAK2, CALR, or MPL in primary myelofibrosis |
| Q40497461 | Clinical features and outcomes of patients with primary myelofibrosis in Japan: report of a 17-year nationwide survey by the Idiopathic Disorders of Hematopoietic Organs Research Committee of Japan |
| Q40506480 | Clinical features and prognostic factors in primary myelofibrosis patients under 45 years old |
| Q34276194 | Clinical significance of microcytosis in patients with primary myelofibrosis |
| Q54385552 | Clinicopathologic characteristics of prefibrotic-early primary myelofibrosis in Chinese patients. |
| Q35217865 | Clonal evolution revealed by whole genome sequencing in a case of primary myelofibrosis transformed to secondary acute myeloid leukemia |
| Q35391230 | Coexistence of plasma cell dyscrasia with prefibrotic stage of primary myelofibrosis: a case report |
| Q40297890 | Coexistence of primary myelofibrosis and chronic lymphocytic leukaemia: treatment of two different diseases with one agent |
| Q44219582 | Coincidence of chronic idiopathic myelofibrosis and chronic lymphocytic leukaemia. A rare phenomenon? |
| Q36817560 | Comorbidities predict worse prognosis in patients with primary myelofibrosis |
| Q44604523 | Comparative clinical-cytological analysis of chronic myeloleukemia and primary myelofibrosis |
| Q48138032 | Comparison of JAK2(V617F) -positive essential thrombocythaemia and early primary myelofibrosis: The impact of mutation burden and histology |
| Q64114551 | Comparison of Outcomes of Allogeneic Transplantation for Primary Myelofibrosis among Hematopoietic Stem Cell Source Groups |
| Q33390032 | Comparison of different criteria for the diagnosis of primary myelofibrosis reveals limited clinical utility for measurement of serum lactate dehydrogenase |
| Q82607138 | Comparison of prognostic scoring systems in primary myelofibrosis |
| Q33595912 | Comparison of the Mutational Profiles of Primary Myelofibrosis, Polycythemia Vera, and Essential Thrombocytosis |
| Q87585544 | Complex cytogenetic findings in the bone marrow of a chronic idiopathic myelofibrosis patient |
| Q42077896 | Comprehensive whole-genome sequencing of an early-stage primary myelofibrosis patient defines low mutational burden and non-recurrent candidate genes |
| Q81548598 | Constitutional trisomy 8 mosaicism in primary myelofibrosis: relevance to clinical practice and warning for trisomy 8 studies |
| Q92340076 | Constitutive STAT5 phosphorylation in CD34+ cells of patients with primary myelofibrosis: Correlation with driver mutation status and disease severity |
| Q86898785 | Construction of gene/protein interaction networks for primary myelofibrosis and KEGG pathway-enrichment analysis of molecular compounds |
| Q56028458 | Conventional and Investigational Therapy for Primary Myelofibrosis |
| Q92741282 | Copy number alterations and copy-neutral loss of heterozygosity in Ukrainian patients with primary myelofibrosis |
| Q35987416 | Correction of anemia in a transfusion-dependent patient with primary myelofibrosis receiving iron chelation therapy with deferasirox (Exjade, ICL670). |
| Q35603419 | Correction of the abnormal trafficking of primary myelofibrosis CD34+ cells by treatment with chromatin-modifying agents |
| Q33422099 | Correlation of JAK2V617F mutational status in primary myelofibrosis with clinico-hematologic characteristics and international prognostic scoring system scoring: a single center experience |
| Q36571372 | Current diagnostic criteria for the chronic myeloproliferative disorders (MPD) essential thrombocythemia (ET), polycythemia vera (PV) and chronic idiopathic myelofibrosis (CIMF). |
| Q44471407 | Current views on the pathogenesis and treatment of spontaneous (primary) myelofibrosis |
| Q69597638 | Cytogenetic and molecular studies in primary myelofibrosis |
| Q39721069 | Cytogenetic studies in twelve patients with primary myelofibrosis and myeloid metaplasia |
| Q36283097 | Cytogenetics, JAK2 and MPL mutations in polycythemia vera, primary myelofibrosis and essential thrombocythemia |
| Q33393245 | DIPSS plus: a refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status |
| Q36267848 | DNMT3A mutational analysis in primary myelofibrosis, chronic myelomonocytic leukemia and advanced phases of myeloproliferative neoplasms |
| Q108863237 | Data‐driven analysis of the kinetics of the JAK2V617F allele burden and blood cell counts during hydroxyurea treatment of patients with polycythemia vera, essential thrombocythemia, and primary myelofibrosis |
| Q64259344 | Decitabine combined with all-trans retinoic acid as treatment in a case of primary myelofibrosis transforming into acute myeloid leukaemia |
| Q41838790 | Defective erythropoiesis in primary myelofibrosis associated with a chromosome 11 abnormality |
| Q79940087 | Development of ET, primary myelofibrosis and PV in mice expressing JAK2 V617F |
| Q58790216 | Development of a prognostically relevant cachexia index in primary myelofibrosis using serum albumin and cholesterol levels |
| Q64055197 | Development of a symptom assessment in patients with myelofibrosis: qualitative study findings |
| Q87389508 | Development of monocytosis in patients with primary myelofibrosis indicates an accelerated phase of the disease |
| Q78732409 | Diagnostic differentiation of essential thrombocythaemia from thrombocythaemias associated with chronic idiopathic myelofibrosis by discriminate analysis of bone marrow features--a clinicopathological study on 272 patients |
| Q58448907 | Differences in presenting features, outcome and prognostic models in patients with primary myelofibrosis and post-polycythemia vera and/or post-essential thrombocythemia myelofibrosis treated with ruxolitinib. New perspective of the MYSEC-PM in a lar |
| Q83576604 | Different immunophenotypical apoptotic profiles characterise megakaryocytes of essential thrombocythaemia and primary myelofibrosis |
| Q79687137 | Different involvement of the megakaryocytic lineage by the JAK2 V617F mutation in Polycythemia vera, essential thrombocythemia and chronic idiopathic myelofibrosis |
| Q44292097 | Differential diagnosis of myelofibrosis based on WHO 2008 criteria: acute panmyelosis with myelofibrosis, acute megakaryoblastic leukemia with myelofibrosis, primary myelofibrosis and myelodysplastic syndrome with myelofibrosis |
| Q42388540 | Discrepancies of applying primary myelofibrosis prognostic scores for patients with post polycythemia vera/essential thrombocytosis myelofibrosis |
| Q35525312 | Discrepancy in diagnosis of primary myelofibrosis between referral and tertiary care centers |
| Q34419687 | Disease burden at the progenitor level is a feature of primary myelofibrosis: a multivariable analysis of 164 JAK2 V617F-positive myeloproliferative neoplasm patients |
| Q91762088 | Distinguishing autoimmune myelofibrosis from primary myelofibrosis |
| Q37231416 | Does primary myelofibrosis involve a defective stem cell niche? From concept to evidence. |
| Q47209528 | Driver mutations and prognosis in primary myelofibrosis: Mayo-Careggi MPN alliance study of 1,095 patients. |
| Q47283891 | Driver mutations in primary myelofibrosis and their implications |
| Q79751355 | Dualism of mixed chimerism between hematopoiesis and stroma in chronic idiopathic myelofibrosis after allogeneic stem cell transplantation |
| Q33366694 | Dynamics of bone marrow changes in patients with chronic idiopathic myelofibrosis following allogeneic stem cell transplantation |
| Q44509200 | Dynamics of fibrosis in chronic idiopathic (primary) myelofibrosis during therapy: a follow-up study on 309 patients |
| Q89931995 | Early detection of pulmonary hypertension in primary myelofibrosis: The role of echocardiography, cardiopulmonary exercise testing, and biomarkers |
| Q89484219 | Early/prefibrotic primary myelofibrosis in patients who were initially diagnosed with essential thrombocythemia |
| Q64067209 | Efficacy of ruxolitinib retreatment in a patient with high-risk myelofibrosis using the international prognostic scoring system |
| Q46618008 | Emergence of therapy-unrelated CML on a background of BCR-ABL-negative JAK2V617F-positive chronic idiopathic myelofibrosis |
| Q35113081 | Enhanced expression of Stim, Orai, and TRPC transcripts and proteins in endothelial progenitor cells isolated from patients with primary myelofibrosis |
| Q88348986 | Erythematous skin lesions with necrotic centers on lower extremities due to the use of ruxolitinib for primary myelofibrosis |
| Q48009616 | Erythropoiesis stimulating agents have limited therapeutic activity in transfusion-dependent patients with primary myelofibrosis regardless of serum erythropoietin level |
| Q36634607 | Essential thrombocythemia or chronic idiopathic myelofibrosis? A single-center study based on hematopoietic bone marrow histology. |
| Q83743618 | Essential thrombocythemia versus early primary myelofibrosis: a multicenter study to validate the WHO classification |
| Q47321525 | Essential thrombocythemia vs. pre-fibrotic/early primary myelofibrosis: discrimination by laboratory and clinical data |
| Q35794415 | European Bone Marrow Working Group trial on reproducibility of World Health Organization criteria to discriminate essential thrombocythemia from prefibrotic primary myelofibrosis |
| Q42752823 | Evading Capture by Residual Disease Monitoring: Extramedullary Manifestation of JAK2 V617F-Positive Primary Myelofibrosis After Allogeneic Stem Cell Transplantation |
| Q41596288 | Evaluation of Short-Term Ruxolitinib Tapering Strategy Before Allogeneic Stem Cell Transplantation for Primary Myelofibrosis Through the Transition of Serum Cytokines and Growth Factors. |
| Q35244917 | Evaluation of plitidepsin in patients with primary myelofibrosis and post polycythemia vera/essential thrombocythemia myelofibrosis: results of preclinical studies and a phase II clinical trial |
| Q81921928 | Evaluation of survival risk scores in primary myelofibrosis: a Brazilian experience from a single institution |
| Q92859333 | Evidence for prevention of renal dysfunction associated with primary myelofibrosis by cytoreductive therapy |
| Q34247430 | Evidence that prefibrotic myelofibrosis is aligned along a clinical and biological continuum featuring primary myelofibrosis |
| Q44273829 | Evolution of myelofibrosis in chronic idiopathic myelofibrosis as evidenced in sequential bone marrow biopsy specimens |
| Q70346994 | Excess of blood group B in primary myelofibrosis |
| Q95661385 | Expansion of paroxysmal nocturnal hemoglobinuria clones in MPLW515L mutation harboring primary myelofibrosis |
| Q33374192 | Expression profiling of apoptosis-related genes in megakaryocytes: BNIP3 is downregulated in primary myelofibrosis |
| Q89741852 | Extramedullary blastic transformation of primary myelofibrosis in the form of disseminated myeloid sarcoma: a case report and review of the literature |
| Q33711600 | F-18-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography Appearance of Extramedullary Hematopoesis in a Case of Primary Myelofibrosis |
| Q49567544 | Fatal Disseminated Tuberculosis during Treatment with Ruxolitinib Plus Prednisolone in a Patient with Primary Myelofibrosis: A Case Report and Review of the Literature |
| Q45204139 | Fatal hepatic failure associated with graft rejection following reduced-intensity stem-cell transplantation for chronic idiopathic myelofibrosis (CIMF). |
| Q96769699 | Favorable COVID-19 course despite significant comorbidities in a ruxolitinib-treated patient with primary myelofibrosis |
| Q36116382 | Fibrogenesis in Primary Myelofibrosis: Diagnostic, Clinical, and Therapeutic Implications |
| Q67061019 | Fibrous long spacing-like fibers in the bone marrow of primary myelofibrosis |
| Q88573645 | Focal segmental glomerulosclerosis in a patient with prefibrotic primary myelofibrosis |
| Q41280768 | Frequency and allele burden of CALR mutations in Chinese with essential thrombocythemia and primary myelofibrosis without JAK2(V617F) or MPL mutations |
| Q61050092 | Frequency and clinical correlates of JAK2 46/1 (GGCC) haplotype in primary myelofibrosis |
| Q51222706 | Frequency of Calreticulin (CALR) Mutation and Its Clinical Prognostic Significance in Essential Thrombocythemia and Primary Myelofibrosis: A Meta-analysis. |
| Q104571700 | GATA1 downregulation in prefibrotic and fibrotic stages of primary myelofibrosis and in the myelofibrotic progression of other myeloproliferative neoplasms |
| Q50201003 | GATA1 insufficiencies in primary myelofibrosis and other hematopoietic disorders: consequences for therapy |
| Q81202252 | GATA1 is overexpressed in patients with essential thrombocythemia and polycythemia vera but not in patients with primary myelofibrosis or chronic myelogenous leukemia |
| Q100534945 | Gamma-Delta T-Cell Lymphoma Following Allogeneic Stem Cell Transplant for Primary Myelofibrosis |
| Q47608808 | Generation and characterization of a human induced pluripotent stem (iPS) cell line derived from an acute myeloid leukemia patient evolving from primary myelofibrosis carrying the CALR 52bp deletion and the ASXL1 p.R693X mutation |
| Q59135610 | Genetic predictors of response to specific drugs in primary myelofibrosis |
| Q53484896 | Genomic and Clinicopathologic Features of Primary Myelofibrosis With Isolated 13q Deletion. |
| Q92514010 | Genomic characterization in triple-negative primary myelofibrosis and other myeloid neoplasms with bone marrow fibrosis |
| Q82299413 | Grade of bone marrow fibrosis is associated with relevant hematological findings-a clinicopathological study on 865 patients with chronic idiopathic myelofibrosis |
| Q70097671 | Granulocytic and stromal progenitors in the bone marrow of patients with primary myelofibrosis |
| Q71048343 | Granulocytic sarcoma of megakaryoblastic differentiation complicating chronic idiopathic myelofibrosis |
| Q53394024 | Granulocytic sarcoma of megakaryoblastic differentiation in the lymph nodes terminating as acute megakaryoblastic leukemia in a case of chronic idiopathic myelofibrosis persisting for 16 years. |
| Q69714990 | Granulopoiesis-supporting effects of marrow stromal cells in continuous culture from patients with primary myelofibrosis |
| Q33489436 | Hematological remission of primary myelofibrosis with antiphospholipid antibody following treatment of azathioprine |
| Q36275880 | Hematopathologic findings in chronic idiopathic myelofibrosis |
| Q73943012 | Hemoglobin F in primary myelofibrosis and in myelodysplasia |
| Q61050077 | Hemoglobin levels and circulating blasts are two easily evaluable diagnostic parameters highly predictive of leukemic transformation in primary myelofibrosis |
| Q92530159 | Herpes simplex vegetans in a patient with primary myelofibrosis |
| Q83796932 | High expression of carcinoembryonic antigen-related cell adhesion molecule (CEACAM) 6 and 8 in primary myelofibrosis |
| Q70378186 | Histological study of intrahepatic cavernous transformation in a patient with primary myelofibrosis and portal venous thrombosis |
| Q64230694 | Homozygous CALR Mutation in Primary Myelofibrosis and Its Effect on Disease Phenotype: A Case Report and Review of the Literature |
| Q44687562 | Hydroxyurea-induced pneumonitis in a patient with chronic idiopathic myelofibrosis after prolonged drug exposure |
| Q91175322 | Hypersegmentation of Granulocytes and Monocytes in a Patient with Primary Myelofibrosis Treated with Hydroxycarbamide |
| Q35835653 | IDH mutations in primary myelofibrosis predict leukemic transformation and shortened survival: clinical evidence for leukemogenic collaboration with JAK2V617F |
| Q33388851 | Identification during the follow-up of time-dependent prognostic factors for the competing risks of death and blast phase in primary myelofibrosis: a study of 172 patients |
| Q54477923 | Identification of MPL W515L/K mutations in patients with primary myelofibrosis and essential thrombocythaemia by allele-specific polymerase chain reaction. |
| Q84474149 | Identification of a novel TEL-Lyn fusion gene in primary myelofibrosis |
| Q33385124 | Identification of patients with poorer survival in primary myelofibrosis based on the burden of JAK2V617F mutated allele |
| Q41665045 | Identification of potential therapeutic target genes and miRNAs for primary myelofibrosis with microarray analysis |
| Q38116911 | Idiopathic myelofibrosis in children: primary myelofibrosis, essential thrombocythemia, or transient process? |
| Q89108370 | Immunohistochemical staining of transcription factor NFE2 for the discrimination of primary myelofibrosis from essential thrombocythemia |
| Q93210908 | Immunoproteasome Genes Are Modulated in CD34+ JAK2V617F Mutated Cells from Primary Myelofibrosis Patients |
| Q93091989 | Impact of 2016 WHO diagnosis of early and overt primary myelofibrosis on presentation and outcome of 232 patients treated with ruxolitinib |
| Q53096529 | Impact of ruxolitinib on the natural history of primary myelofibrosis: a comparison of the DIPSS and the COMFORT-2 cohorts. |
| Q72110007 | Importance of bioptic research in the study of primary myelofibrosis |
| Q39953296 | Improved Survival of Calreticulin-Mutated Patients Compared With Janus Kinase 2 in Primary Myelofibrosis: A Meta-Analysis |
| Q43957434 | Improved survival in patients with CALR1 compared to CALR2 mutated primary myelofibrosis: a meta-analysis |
| Q37532323 | Improved survival in red blood cell transfusion dependent patients with primary myelofibrosis (PMF) receiving iron chelation therapy. |
| Q33434654 | Improvement of Anaemia in Patients with Primary Myelofibrosis by Low-Dose Thalidomide and Prednisone |
| Q53126695 | Improving survival trends in primary myelofibrosis: an international study. |
| Q53298023 | Incidence of leukaemia in patients with primary myelofibrosis and RBC-transfusion-dependence. |
| Q64284961 | Incidence of myeloproliferative neoplasms in Calgary, Alberta, Canada |
| Q35088483 | Incidence, clinical features, and prognostic impact of CALR exon 9 mutations in essential thrombocythemia and primary myelofibrosis: an experience of a single tertiary hospital in Korea |
| Q53558683 | Increased angiogenesis in chronic idiopathic myelofibrosis: vascular endothelial growth factor as a prominent angiogenic factor. |
| Q35053286 | Increased angiogenesis in primary myelofibrosis: latent transforming growth factor-β as a possible angiogenic factor |
| Q38570614 | Indication and management of allogeneic stem cell transplantation in primary myelofibrosis: a consensus process by an EBMT/ELN international working group |
| Q85054368 | Induction of complete remission of acute myeloid leukaemia by pegylated interferon-alpha-2a in a patient with transformed primary myelofibrosis |
| Q64019035 | Induction of remission after donor leucocyte infusion for the treatment of relapsed chronic idiopathic myelofibrosis following allogeneic transplantation: evidence for a 'graft vs. myelofibrosis' effect |
| Q26774212 | Inflammation as a Keystone of Bone Marrow Stroma Alterations in Primary Myelofibrosis |
| Q73170995 | Initial (prefibrotic) stages of idiopathic (primary) myelofibrosis (IMF) - a clinicopathological study |
| Q92270548 | Integrating clinical, morphological, and molecular data to assess prognosis in patients with primary myelofibrosis at diagnosis: A practical approach |
| Q80934673 | Interphase FISH screening for the LCR-mediated common rearrangement of isochromosome 17q in primary myelofibrosis |
| Q91771093 | Intestinal Behçet's Disease with Primary Myelofibrosis Involving Trisomy 8 |
| Q34137469 | Intestinal obstruction caused by extramedullary hematopoiesis and ascites in primary myelofibrosis |
| Q88460039 | Intracranial extramedullary hematopoiesis in primary myelofibrosis |
| Q36862456 | Involvement of TGFβ1 in autocrine regulation of proplatelet formation in healthy subjects and patients with primary myelofibrosis |
| Q42134799 | Is it Primary Myelofibrosis or Chronic Lymphocytic Leukemia Related Secondary Myelofibrosis? |
| Q34419889 | Is it chronic idiopathic myelofibrosis, myelofibrosis with myeloid metaplasia, chronic megakaryocytic-granulocytic myelosis, or chronic megakaryocytic leukemia? Further thoughts on the nosology of the clonal myeloid disorders |
| Q53534285 | Isochromosome 17q10 associated with basophilia in primary myelofibrosis while with JAK2 inhibitor. |
| Q47794463 | Isoderivative of deleted chromosome 20 in primary myelofibrosis (PMF) characterized by molecular cytogenetics and array CGH. |
| Q34652224 | JAK2 V617F genotype is a strong determinant of blast transformation in primary myelofibrosis |
| Q46060451 | JAK2 V617F mutation positive primary myelofibrosis with concomitant t(9;11;22)(q34;p15;q11.2) but no BCR/ABL fusion |
| Q36563107 | JAK2 V617F, MPL W515L and JAK2 Exon 12 Mutations in Chinese Patients with Primary Myelofibrosis |
| Q35778568 | JAK2 V617F, MPL, and CALR Mutations in Korean Patients with Essential Thrombocythemia and Primary Myelofibrosis |
| Q91818077 | JAK2 exon 12 mutations in cases with JAK2V617F-negative polycythemia vera and primary myelofibrosis |
| Q35548472 | JAK2 exon 14 skipping in patients with primary myelofibrosis: a minor splice variant modulated by the JAK2-V617F allele burden |
| Q53185401 | JAK2 germline genetic variation affects disease susceptibility in primary myelofibrosis regardless of V617F mutational status: nullizygosity for the JAK2 46/1 haplotype is associated with inferior survival. |
| Q84251634 | JAK2(V617F) allele burden discriminates essential thrombocythemia from a subset of prefibrotic-stage primary myelofibrosis |
| Q50137133 | JAK2-mutated langerhans cell histiocytosis associated with primary myelofibrosis treated with ruxolitinib |
| Q54257346 | JAK2V617F molecular remission in a primary myelofibrosis patient treated with ruxolitinib. |
| Q53136481 | Leukemia risk models in primary myelofibrosis: an International Working Group study. |
| Q61443559 | Leukemic transformation among 1306 patients with primary myelofibrosis: risk factors and development of a predictive model |
| Q42854495 | Leukemic transformation driven by an ASXL1 mutation after a JAK2V617F-positive primary myelofibrosis: clonal evolution and hierarchy revealed by next-generation sequencing. |
| Q70975795 | Leukemic transformation of primary myelofibrosis: immunophenotype, genotype and growth characteristics of blast cells |
| Q68346136 | Liver involvement at diagnosis of primary myelofibrosis: a clinicopathological study of twenty-two cases |
| Q87506153 | Long non-coding RNAs in primary myelofibrosis: the dark matter in hematopoietic progenitor cells? |
| Q80542642 | Low JAK2V617F allele burden in primary myelofibrosis, compared to either a higher allele burden or unmutated status, is associated with inferior overall and leukemia-free survival |
| Q90853694 | Luspatercept for the treatment of anemia in myelodysplastic syndromes and primary myelofibrosis |
| Q88512523 | MIPSS70+ Version 2.0: Mutation and Karyotype-Enhanced International Prognostic Scoring System for Primary Myelofibrosis |
| Q84552193 | MPL immunohistochemical expression as a novel marker for essential thrombocythemia and primary myelofibrosis differential diagnosis |
| Q49191669 | Marked elevation of serum lactate dehydrogenase in primary myelofibrosis: clinical and prognostic correlates |
| Q92576839 | Massive megakaryocyte clustering in triple-negative primary myelofibrosis associated with an unusual cytogenetic aberration |
| Q85200885 | Massive splenomegaly and extramedullary hematopoiesis in chronic idiopathic myelofibrosis |
| Q33517074 | Mature survival data for 176 patients younger than 60 years with primary myelofibrosis diagnosed between 1976 and 2005: evidence for survival gains in recent years |
| Q41980585 | Mayor erythropoietic response after deferasirox treatment in a transfusion-dependent anemic patient with primary myelofibrosis |
| Q87586160 | Mega-dose methylprednisolone (MDMP) for chronic idiopathic myelofibrosis |
| Q86175434 | Megadosemethilprednisolone (mdmp) For Primary Myelofibrosis (pmf) |
| Q84670165 | Megakaryocyte dysplasia in primary myelofibrosis |
| Q42679673 | Megakaryocytic morphology and clinical parameters in essential thrombocythemia, polycythemia vera, and primary myelofibrosis with and without JAK2 V617F. |
| Q61050103 | Mesenchymal stem cells from JAK2V617F mutant patients with primary myelofibrosis do not harbor JAK2 mutant allele |
| Q57047996 | Mesenchymal stem cells in myeloproliferative disorders - focus on primary myelofibrosis |
| Q33408634 | Metastatic splenic angiosarcoma presenting with thrombocytopenia and bone marrow fibrosis mimicking idiopathic thrombocytopenic purpura and primary myelofibrosis: a diagnostic challenge |
| Q35975009 | MicroRNA Expression Analysis in Patients with Primary Myelofibrosis, Polycythemia vera and Essential Thrombocythemia. |
| Q34708484 | MicroRNA expression profile in granulocytes from primary myelofibrosis patients. |
| Q33509139 | MicroRNA expression profiling of megakaryocytes in primary myelofibrosis and essential thrombocythemia |
| Q38984558 | Molecular Pathogenesis and Clinical Significance of Driver Mutations in Primary Myelofibrosis: A Review |
| Q45329205 | Molecular characterization of a transformation from primary myelofibrosis into polycythemia vera: a case report |
| Q27853374 | Molecular correlates of anemia in primary myelofibrosis: a significant and independent association with U2AF1 mutations |
| Q89384025 | Molecular correlates of anemia in primary myelofibrosis: a significant and independent association with U2AF1 mutations |
| Q80070172 | Monocytosis is an adverse prognostic factor for survival in younger patients with primary myelofibrosis |
| Q83750467 | Monosomal karyotype in primary myelofibrosis is detrimental to both overall and leukemia-free survival |
| Q50890627 | Morphologic and cytogenetic differences between post-polycythemic myelofibrosis and primary myelofibrosis in fibrotic stage. |
| Q71981658 | Multiple myeloma with bone marrow biopsy features simulating concomitant chronic idiopathic myelofibrosis |
| Q93136758 | Mutation profile in Indian primary myelofibrosis patients and its clinical implications |
| Q40972817 | Mutation status of essential thrombocythemia and primary myelofibrosis defines clinical outcome |
| Q49893101 | Mutational analysis aids the diagnosis of primary myelofibrosis with atypical morphology. |
| Q48205239 | Myeloid neoplasms with features intermediate between primary myelofibrosis and chronic myelomonocytic leukemia. |
| Q35188877 | Myeloproliferative neoplasms working group consensus recommendations for diagnosis and management of primary myelofibrosis, polycythemia vera, and essential thrombocythemia |
| Q44907558 | Mössbauer spectroscopy of the iron cores in human liver ferritin, ferritin in normal human spleen and ferritin in spleen from patient with primary myelofibrosis: preliminary results of comparative analysis |
| Q80503566 | NPM1-mutated acute myeloid leukaemia occurring in JAK2-V617F+ primary myelofibrosis: de-novo origin? |
| Q96022956 | Neoplastic fibrocytes play an essential role in bone marrow fibrosis in Jak2V617F-induced primary myelofibrosis mice |
| Q38652831 | Nephrotic syndrome in primary myelofibrosis with renal extramedullary hematopoiesis and glomerulopathy in the JAK inhibitor era. |
| Q33377528 | New and old treatment modalities in primary myelofibrosis |
| Q79802927 | New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment |
| Q90866053 | Novel lysyl oxidase inhibitors attenuate hallmarks of primary myelofibrosis in mice |
| Q91365326 | Novel targets to cure primary myelofibrosis from studies on Gata1low mice |
| Q53461061 | Nuclear factor-erythroid 2, nerve growth factor receptor, and CD34-microvessel density are differentially expressed in primary myelofibrosis, polycythemia vera, and essential thrombocythemia. |
| Q38894833 | Obstructive Uropathy as an Initial Presentation of Primary Myelofibrosis: Case Report and Review of Literature |
| Q36512816 | One thousand patients with primary myelofibrosis: the mayo clinic experience |
| Q61627760 | Osteogenic Potential of Mesenchymal Stromal Cells Contributes to Primary Myelofibrosis |
| Q92972165 | Osteolytic Lesions in Primary Myelofibrosis and Effect of Ruxolitinib Therapy: Report of a Case and Literature Review |
| Q81896220 | Osteosclerosis in advanced chronic idiopathic myelofibrosis is associated with endothelial overexpression of osteoprotegerin |
| Q93059368 | Overview of the Mutational Landscape in Primary Myelofibrosis and Advances in Novel Therapeutics |
| Q95517421 | Paediatrics primary myelofibrosis and acute stroke: A rare presentation |
| Q33753094 | Pathological interactions between hematopoietic stem cells and their niche revealed by mouse models of primary myelofibrosis |
| Q33442613 | Patients with post-essential thrombocythemia and post-polycythemia vera differ from patients with primary myelofibrosis |
| Q90734553 | Pentraxin-3 plasma levels correlate with tumour burden and overall survival in patients with primary myelofibrosis |
| Q90292806 | Persistent Basophilia May Suggest an "Accelerated Phase" in the Evolution of CALR-Positive Primary Myelofibrosis Toward Acute Myeloid Leukemia |
| Q41876172 | Ph-negative chronic myeloproliferative neoplasm (primary myelofibrosis) - as one of the reasons of the budd-Chiari syndrome |
| Q33407924 | Phase II trial of panobinostat, an oral pan-deacetylase inhibitor in patients with primary myelofibrosis, post-essential thrombocythaemia, and post-polycythaemia vera myelofibrosis |
| Q33492800 | Plasma soluble interleukin-2 receptor in patients with primary myelofibrosis |
| Q84556367 | Polymorphisms of tumor necrosis factor gene in primary myelofibrosis |
| Q50990686 | Population pharmacokinetic analysis of orally-administered ruxolitinib (INCB018424 Phosphate) in patients with primary myelofibrosis (PMF), post-polycythemia vera myelofibrosis (PPV-MF) or post-essential thrombocythemia myelofibrosis (PET MF). |
| Q43740667 | Possibility of transformation of primary myelofibrosis to ALL without JAK2V617F mutation. |
| Q88527855 | Post-ET and Post-PV Myelofibrosis: Updates on a Distinct Prognosis from Primary Myelofibrosis |
| Q81243631 | Post-splenectomy pseudohyperkalemia in a patient with chronic idiopathic myelofibrosis and thrombocytosis |
| Q84401083 | Practical application and clinical impact of the WHO histopathological criteria on bone marrow biopsy for the diagnosis of essential thrombocythemia versus prefibrotic primary myelofibrosis |
| Q38764516 | Pre-fibrotic/early primary myelofibrosis vs. WHO-defined essential thrombocythemia: The impact of minor clinical diagnostic criteria on the outcome of the disease |
| Q47427464 | Predicting pathogenic genes for primary myelofibrosis based on a system‑network approach |
| Q53147067 | Predictors of greater than 80% 2-year mortality in primary myelofibrosis: a Mayo Clinic study of 884 karyotypically annotated patients. |
| Q79805640 | Prefibrotic chronic idiopathic myelofibrosis--a diagnostic enigma? |
| Q48176317 | Prefibrotic versus overtly fibrotic primary myelofibrosis: clinical, cytogenetic, molecular and prognostic comparisons. |
| Q81266514 | Prevention of hepatic infarction as acute-phase complication of TIPS by temporary balloon occlusion in a patient with primary myelofibrosis |
| Q38736858 | Primary Myelofibrosis Presenting as Extramedullary Hematopoiesis in a Transplanted Liver Graft: Case Report and Review of the Literature. |
| Q36702208 | Primary myelofibrosis (PMF), post polycythemia vera myelofibrosis (post-PV MF), post essential thrombocythemia myelofibrosis (post-ET MF), blast phase PMF (PMF-BP): Consensus on terminology by the international working group for myelofibrosis resear |
| Q41869469 | Primary myelofibrosis and extramedullary blastic transformation with hemophagocytosis |
| Q80292560 | Primary myelofibrosis and its paraneoplastic stromal effects |
| Q38931426 | Primary myelofibrosis and its targeted therapy. |
| Q47128531 | Primary myelofibrosis and pregnancy outcomes after low molecular-weight heparin administration: A case report and literature review |
| Q41838687 | Primary myelofibrosis and the "bad seeds in bad soil" concept |
| Q44527387 | Primary myelofibrosis and the myeloproliferative neoplasms: the role of individual variation |
| Q35732435 | Primary myelofibrosis associated glomerulopathy: significant improvement after therapy with ruxolitinib |
| Q69727058 | Primary myelofibrosis associated with marked pulmonary fibrosis and hematopoiesis: report of a case (author's transl) |
| Q68964494 | Primary myelofibrosis associated with portal venous thrombotic occlusion and cavernous transformation around the biliary tree |
| Q95532895 | Primary myelofibrosis but not autoimmune myelofibrosis accompanied by Sjögren's syndrome and primary biliary cirrhosis in a patient with trisomy 8 mosaic: a case report and literature review |
| Q55517410 | Primary myelofibrosis evolving to an aplastic appearing marrow. |
| Q81513345 | Primary myelofibrosis in a patient who developed primary biliary cirrhosis, autoimmune hemolytic anemia and fibrillary glomerulonephritis |
| Q40760147 | Primary myelofibrosis in children: report of 4 cases |
| Q46552200 | Primary myelofibrosis is the most frequent myeloproliferative neoplasm associated with del(5q): clinicopathologic comparison of del(5q)-positive and -negative cases |
| Q90380166 | Primary myelofibrosis marrow-derived CD14+/CD34- monocytes induce myelofibrosis-like phenotype in immunodeficient mice and give rise to megakaryocytes |
| Q48140163 | Primary myelofibrosis presenting in acute promyelocytic transformation. |
| Q54712998 | Primary myelofibrosis relapsed with duodenal myeloid sarcoma after allogeneic stem cell transplantation. |
| Q67971116 | Primary myelofibrosis successfully treated with allogeneic bone marrow transplantation |
| Q50784149 | Primary myelofibrosis terminated in basophilic leukemia and successful allogeneic bone marrow transplantation. |
| Q40764477 | Primary myelofibrosis terminating in megakaryoblastic crisis |
| Q53572232 | Primary myelofibrosis terminating in myeloblastic transformation within a short time. |
| Q104509277 | Primary myelofibrosis with concurrent CALR and MPL mutations: A case report |
| Q39871173 | Primary myelofibrosis with concurrent precursor T-cell lymphoblastic lymphoma of the spleen in a 26-year-old patient |
| Q51025938 | Primary myelofibrosis with or without mutant MPL: comparison of survival and clinical features involving 603 patients. |
| Q37956603 | Primary myelofibrosis: 2012 update on diagnosis, risk stratification, and management |
| Q38076672 | Primary myelofibrosis: 2013 update on diagnosis, risk-stratification, and management |
| Q50462637 | Primary myelofibrosis: 2014 update on diagnosis, risk-stratification, and management |
| Q39015300 | Primary myelofibrosis: 2017 update on diagnosis, risk-stratification, and management |
| Q90435653 | Primary myelofibrosis: 2019 update on diagnosis, risk-stratification and management |
| Q102071390 | Primary myelofibrosis: 2021 update on diagnosis, risk-stratification and management |
| Q38722134 | Primary myelofibrosis: Older age and high JAK2V617F allele burden are associated with elevated plasma high-sensitivity C-reactive protein levels and a phenotype of progressive disease. |
| Q40702853 | Primary myelofibrosis: a detailed statistical analysis of the clinicopathological variables influencing survival. |
| Q41186952 | Primary myelofibrosis: current therapeutic options |
| Q36727581 | Primary myelofibrosis: risk stratification by IPSS identifies patients with poor clinical outcome. |
| Q92465029 | Primary myelofibrosis: spectrum of imaging features and disease-related complications |
| Q37306795 | Primary myelofibrosis: update on definition, pathogenesis, and treatment. |
| Q44022260 | Primary myelofibrosis: when the clone manifests with Rh phenotype splitting |
| Q38087202 | Problems and pitfalls regarding WHO-defined diagnosis of early/prefibrotic primary myelofibrosis versus essential thrombocythemia |
| Q82320486 | Prognosis and survivorship in primary myelofibrosis |
| Q38926804 | Prognosis of Primary Myelofibrosis in the Genomic Era |
| Q74629000 | Prognostic impact of apoptosis and proliferation in idiopathic (primary) myelofibrosis |
| Q79924038 | Prognostic implications of the European consensus for grading of bone marrow fibrosis in chronic idiopathic myelofibrosis |
| Q84133581 | Prognostic relevance of cytogenetic abnormalities in primary myelofibrosis: comparison of recent reports from Japan, the Mayo Clinic and MD Anderson Cancer Center |
| Q33443649 | Prognostic significance of a comprehensive histologic evaluation of reticulin fibrosis, collagen deposition and osteosclerosis in primary myelofibrosis patients |
| Q41049859 | Progression of primary myelofibrosis to polycythemia vera: A case report |
| Q54360954 | Proliferation in liquid culture of megakaryocytes from the blood of patients with primary myelofibrosis and other myeloproliferative disorders. |
| Q34626628 | Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel |
| Q82866294 | Prospective study of combination therapy with low-dose thalidomide plus prednisolone ameliorating cytopenia in primary myelofibrosis |
| Q40727272 | Protein kinase Cɛ inhibition restores megakaryocytic differentiation of hematopoietic progenitors from primary myelofibrosis patients |
| Q53142053 | Pruritus in primary myelofibrosis: clinical and laboratory correlates. |
| Q38815464 | Pruritus in primary myelofibrosis: management options in the era of JAK inhibitors |
| Q57488209 | Pulmonary arterial hypertension in primary myelofibrosis is common and associated with an altered angiogenic status |
| Q40954119 | Pulmonary cryptococcosis in a ruxolitinib-treated patient with primary myelofibrosis |
| Q84760561 | Pyoderma gangrenosum associated with chronic idiopathic myelofibrosis after coronary artery bypass graft surgery |
| Q98731444 | Rapidly progressive cognitive impairment: an unusual presentation of cerebral venous thrombosis caused by JAK2 V617F-positive primary myelofibrosis: A case report |
| Q37224321 | Rare congenital chromosomal aberration dic(X;Y)(p22.33;p11.32) in a patient with primary myelofibrosis |
| Q90574681 | Reactivation of tuberculosis following ruxolitinib therapy for primary myelofibrosis: Case series and literature review |
| Q33375897 | Reappearance of t(12;17)-positive primary myelofibrosis following Ph+ CML cell reduction by imatinib |
| Q50712240 | Recombinant human erythropoietin for the treatment of anaemia in patients with chronic idiopathic myelofibrosis. |
| Q53154624 | Recombinant interferon-α may retard progression of early primary myelofibrosis: a preliminary report. |
| Q80178952 | Recurrent chromosomal aberration at 12q15 in chronic idiopathic myelofibrosis with or without JAK2(V617F) mutation |
| Q34451630 | Red blood cell transfusion-dependency implies a poor survival in primary myelofibrosis irrespective of IPSS and DIPSS |
| Q71021756 | Red cell production and destruction in primary myelofibrosis with reference to the neutrophil and platelet kinetics |
| Q96343908 | Reduced CXCR4-expression on CD34-positive blood cells predicts outcomes of persons with primary myelofibrosis |
| Q37457111 | Reduced-intensity hematopoietic cell transplantation for patients with primary myelofibrosis: a cohort analysis from the center for international blood and marrow transplant research. |
| Q33392291 | Refined cytogenetic-risk categorization for overall and leukemia-free survival in primary myelofibrosis: a single center study of 433 patients |
| Q92570733 | Refractory gout in primary myelofibrosis |
| Q49714886 | Regenerative nodular hyperplasia, portal vein thrombosis and primary myelofibrosis: An unusual triple association |
| Q68386021 | Remission of chronic idiopathic myelofibrosis to busulfan treatment |
| Q69951041 | Remission of chronic idiopathic myelofibrosis to busulphan treatment |
| Q89389886 | Renal complications of primary myelofibrosis |
| Q30557756 | Rescue of a primary myelofibrosis model by retinoid-antagonist therapy |
| Q73215630 | Resident bone marrow macrophages in idiopathic (primary) myelofibrosis (IMF): a histochemical and morphometric study on sequential trephine biopsies |
| Q69844388 | Reticulosarcomatosis in primary myelofibrosis |
| Q33395526 | Reversal of transfusion dependence by tumor necrosis factor inhibitor treatment in a patient with concurrent rheumatoid arthritis and primary myelofibrosis |
| Q54794091 | Revised cytogenetic risk stratification in primary myelofibrosis: analysis based on 1002 informative patients. |
| Q59799223 | Role of TGF-β1/miR-382-5p/SOD2 axis in the induction of oxidative stress in CD34+ cells from primary myelofibrosis |
| Q39015118 | Role of miR-34a-5p in Hematopoietic Progenitor Cells Proliferation and Fate Decision: Novel Insights into the Pathogenesis of Primary Myelofibrosis |
| Q37197964 | Role of neoplastic monocyte-derived fibrocytes in primary myelofibrosis |
| Q41519422 | Ruxolitinib Treatment in a Patient with Primary Myelofibrosis Resistant to Conventional Therapies and Splenectomy: A Case Report |
| Q88009332 | Ruxolitinib for the Treatment of Portal Hypertension in a Patient With Primary Myelofibrosis |
| Q33413637 | Ruxolitinib for the treatment of primary myelofibrosis |
| Q42318760 | Ruxolitinib rechallenge in combination with hydroxyurea is effective in reverting cachexia and reducing blood transfusion demand and splenomegaly symptoms in a patient with primary myelofibrosis |
| Q92059096 | Ruxolitinib therapy is associated with improved renal function in patients with primary myelofibrosis |
| Q42426547 | SETBP1 and miR_4319 dysregulation in primary myelofibrosis progression to acute myeloid leukemia |
| Q42937128 | SETBP1 mutations in 415 patients with primary myelofibrosis or chronic myelomonocytic leukemia: independent prognostic impact in CMML. |
| Q82413474 | SF3B1 mutations in primary myelofibrosis: clinical, histopathology and genetic correlates among 155 patients |
| Q34081581 | SNPs array karyotyping reveals a novel recurrent 20p13 amplification in primary myelofibrosis |
| Q43096810 | SRSF2 and U2AF1 mutations in primary myelofibrosis are associated with JAK2 and MPL but not calreticulin mutation and may independently reoccur after allogeneic stem cell transplantation |
| Q84962229 | SRSF2 mutations in primary myelofibrosis: significant clustering with IDH mutations and independent association with inferior overall and leukemia-free survival |
| Q63728939 | Safety and efficacy of combination therapy of interferon-α2 and ruxolitinib in polycythemia vera and myelofibrosis |
| Q97532854 | Salvage Therapy Using Azacitidine for Relapsed Primary Myelofibrosis after Cord Blood Transplantation |
| Q40930944 | Sclerosing extramedullary hematopoietic tumor presenting as an inguinal mass in a patient with primary myelofibrosis: a diagnostic pitfall |
| Q54444131 | Screening for MPL mutations in essential thrombocythemia and primary myelofibrosis: normal Mpl expression and absence of constitutive STAT3 and STAT5 activation in MPLW515L-positive platelets. |
| Q95654733 | Secondary Pulmonary Alveolar Proteinosis Associated with Primary Myelofibrosis and Ruxolitinib Treatment: An Autopsy Case |
| Q50227193 | Sequential development of chronic myelogenous leukemia and primary myelofibrosis in a patient with history of large B-cell lymphoma treated with radiotherapy and chemotherapy: two myeloid neoplasms with distinct genotypic profiles suggestive of bicl |
| Q34541582 | Sequential treatment of CD34+ cells from patients with primary myelofibrosis with chromatin-modifying agents eliminate JAK2V617F-positive NOD/SCID marrow repopulating cells. |
| Q71709216 | Serum G-CSF levels in primary myelofibrosis and chronic neutrophilic leukemia as estimated by the highly sensitive chemiluminescence enzyme immunoassay (CLEIA) |
| Q68780289 | Serum procollagen-III-peptide as a marker for primary myelofibrosis: effect of anthracyclin |
| Q93096527 | Severe acquired platelet dysfunction because of primary myelofibrosis with full functional and morphological recovery after allogeneic hematopoietic cell transplantation |
| Q81111745 | Severe pulmonary hypertension in chronic idiopathic myelofibrosis |
| Q55250247 | Sex and degree of severity influence the prognostic impact of anemia in primary myelofibrosis: analysis based on 1109 consecutive patients. |
| Q91070371 | Shared and Tissue-Specific Expression Signatures between Bone Marrow from Primary Myelofibrosis and Essential Thrombocythemia |
| Q35808066 | Small RNA Sequencing Uncovers New miRNAs and moRNAs Differentially Expressed in Normal and Primary Myelofibrosis CD34+ Cells |
| Q91929083 | Spectrum of ASXL1 mutations in primary myelofibrosis: prognostic impact of the ASXL1 p.G646Wfs*12 mutation |
| Q49391128 | Splanchnic vein thrombosis as a first manifestation of Primary myelofibrosis |
| Q84552610 | Splenectomy after allogeneic haematopoietic stem cell transplantation in patients with primary myelofibrosis |
| Q71412802 | Splenectomy in primary myelofibrosis: two long-term survivors after splenectomy |
| Q83261758 | Splenectomy produces a rapid but transient decrease of the frequency of circulating CD34+ haematopoietic progenitor cells in primary myelofibrosis |
| Q91427237 | Splenic Marginal Zone Lymphoma with Prominent Myelofibrosis Mimicking Triple-Negative Primary Myelofibrosis |
| Q39177828 | Splenic irradiation provides transient palliation for symptomatic splenomegaly associated with primary myelofibrosis: a report on 14 patients |
| Q66927525 | Static and functional morphology of the pathological platelets in primary myelofibrosis and myeloproliferative syndrome |
| Q38091265 | Stem cell transplantation in primary myelofibrosis of childhood. |
| Q44442079 | Stromal cells in primary myelofibrosis: ultrastructural observations |
| Q36983755 | Subcellular mislocalization of the transcription factor NF-E2 in erythroid cells discriminates prefibrotic primary myelofibrosis from essential thrombocythemia. |
| Q91850505 | Successful engraftment after cord blood transplantation from an HLA-homozygous donor (homo-to-hetero cord blood transplantation) in a primary myelofibrosis patient with broad HLA antibodies |
| Q33396213 | Successful high-dose methylprednisolone therapy in a patient with primary myelofibrosis |
| Q43943999 | Successful treatment of primary myelofibrosis with thrombocytosis during pregnancy with alfa-interferon |
| Q67312777 | Sustained Haematological Remission after Bone Marrow Curettage in a Case of Primary Myelofibrosis |
| Q92819319 | Systematization of analytical studies of polycythemia vera, essential thrombocythemia and primary myelofibrosis, and a meta-analysis of the frequency of JAK2, CALR and MPL mutations: 2000-2018 |
| Q95265855 | Systemic Mastocytosis with Associated Primary Myelofibrosis |
| Q36329321 | Systemic mastocytosis associated with chronic idiopathic myelofibrosis: a distinct subtype of systemic mastocytosis associated with a [corrected] clonal hematological non-mast [corrected] cell lineage disorder carrying the activating point mutations |
| Q90462714 | Systemic mastocytosis with an associated hematological neoplasm masquerading as overt primary myelofibrosis |
| Q82244671 | T-cell post-transplant lymphoproliferative disorder in a patient with chronic idiopathic myelofibrosis following allogeneic PBSC transplantation |
| Q104061417 | TET2 rs1548483 SNP Associating with Susceptibility to Molecularly Annotated Polycythemia Vera and Primary Myelofibrosis |
| Q85344059 | TP53 mutation is rare in primary myelofibrosis |
| Q82340637 | TP53 mutations and polymorphisms in primary myelofibrosis |
| Q89777272 | Targeted deep sequencing in primary myelofibrosis |
| Q35669864 | Tetraspanin CD9 participates in dysmegakaryopoiesis and stromal interactions in primary myelofibrosis |
| Q36364763 | The Clinical Significance of IDH Mutations in Essential Thrombocythemia and Primary Myelofibrosis |
| Q103775611 | The Genetic Basis of Primary Myelofibrosis and Its Clinical Relevance |
| Q28289219 | The Thr224Asn mutation in the VPS45 gene is associated with the congenital neutropenia and primary myelofibrosis of infancy |
| Q79781347 | The dawn of targeted therapy for primary myelofibrosis: opportunities and challenges |
| Q37517151 | The diagnosis and management of polycythemia vera, essential thrombocythemia, and primary myelofibrosis in the JAK2 V617F era. |
| Q92683437 | The evolving understanding of prognosis in post-essential thrombocythemia myelofibrosis and post-polycythemia vera myelofibrosis vs primary myelofibrosis |
| Q50676394 | The gain-of-function JAK2 V617F mutation shifts the phenotype of essential thrombocythemia and chronic idiopathic myelofibrosis to more "erythremic" and less "thrombocythemic": a molecular, histologic, and clinical study. |
| Q90273799 | The germline JAK2 GGCC (46/1) haplotype and survival among 414 molecularly-annotated patients with primary myelofibrosis |
| Q87215715 | The glucocorticoid receptor A3669G SNP is not associated with polycythemia vera, essential thrombocythemia or primary myelofibrosis |
| Q36524055 | The impact of clinicopathological studies on staging and survival in essential thrombocythemia, chronic idiopathic myelofibrosis, and polycythemia rubra vera |
| Q84113405 | The impact of cytogenetic abnormalities on the prognosis of primary myelofibrosis: a prospective survey of 202 cases in Japan |
| Q41981037 | The importance of cytogenetics in polycythemia vera, primary myelofibrosis and essential thrombocythemia |
| Q81600518 | The incidence of myelofibrosis in essential thrombocythaemia, polycythaemia vera and chronic idiopathic myelofibrosis: a retrospective evaluation of sequential bone marrow biopsies |
| Q58455624 | The number of prognostically detrimental mutations and prognosis in primary myelofibrosis: an international study of 797 patients |
| Q46760336 | The presence of JAK2V617F in primary myelofibrosis or its allele burden in polycythemia vera predicts chemosensitivity to hydroxyurea |
| Q61050070 | The prognostic impact of bone marrow fibrosis in primary myelofibrosis |
| Q83141273 | The relationship of the active and latent forms of TGF-β1 with marrow fibrosis in essential thrombocythemia and primary myelofibrosis |
| Q37133762 | The revised World Health Organization diagnostic criteria for polycythemia vera, essential thrombocytosis, and primary myelofibrosis: an alternative proposal |
| Q43162409 | The role of allogeneic SCT in primary myelofibrosis: a British Society for Blood and Marrow Transplantation study. |
| Q36788138 | The role of cytogenetic abnormalities as a prognostic marker in primary myelofibrosis: applicability at the time of diagnosis and later during disease course |
| Q67521329 | The role of the spleen after bone marrow transplantation for primary myelofibrosis |
| Q85158425 | The role of zinc protoporphyrin measurement in the differentiation between primary myelofibrosis and essential thrombocythaemia |
| Q35988523 | Therapeutic benefit of decitabine, a hypomethylating agent, in patients with high-risk primary myelofibrosis and myeloproliferative neoplasm in accelerated or blastic/acute myeloid leukemia phase |
| Q35619066 | Therapy-related changes of the bone marrow in chronic idiopathic myelofibrosis |
| Q35532006 | Thrombosis in essential thrombocytemia and early/prefibrotic primary myelofibrosis: the role of the WHO histological diagnosis |
| Q61050096 | Thrombosis in primary myelofibrosis: incidence and risk factors |
| Q33631390 | Thrombospondin-1 (TSP-1) in primary myelofibrosis (PMF) - a megakaryocyte-derived biomarker which largely discriminates PMF from essential thrombocythemia |
| Q46217111 | Toxic epidermal necrolysis in a patient with primary myelofibrosis receiving thalidomide therapy |
| Q38015562 | Transformation of primary myelofibrosis with 20q- in Philadelphia-positive acute lymphoblastic leukemia: case report and review of literature. |
| Q98958698 | Transforming growth factor β-mediated micromechanics modulates disease progression in primary myelofibrosis |
| Q53089146 | Transfusion Independency and Histological Remission in a Patient with Advanced Primary Myelofibrosis Receiving Iron-Chelation Therapy with Deferasirox. |
| Q54285700 | Transient elastography spleen stiffness measurements in primary myelofibrosis patients: a pilot study in a single centre. |
| Q33488409 | Transient promyelocytic expansion in primary myelofibrosis |
| Q84432948 | Transjugular intrahepatic porto-systemic stent-shunt for therapy of bleeding esophageal varices due to extramedullary hematopoiesis in primary myelofibrosis: a case report |
| Q77308156 | Translocation (2;3)(p21;q26) as the sole anomaly in a case of primary myelofibrosis |
| Q35140853 | Translocation t(3;12)(q26;q21) in JAK2(V617F) Point Mutation Negative Chronic Idiopathic Myelofibrosis: A Case Report |
| Q50512798 | Treatment of patients with primary myelofibrosis using dasatinib. |
| Q95401333 | Treatment of primary myelofibrosis |
| Q82313418 | Trisomy 8 in prefibrotic early stages of chronic idiopathic myelofibrosis: a fluorescence in situ study of bone marrow biopsies |
| Q100642595 | Tuberculosis in Patients with Primary Myelofibrosis During Ruxolitinib Therapy: Case Series and Literature Review |
| Q89466527 | Tuberculosis reactivation related with ruxolitinib in a patient with primary myelofibrosis |
| Q54374932 | Type 1 vs type 2 calreticulin mutations in primary myelofibrosis: differences in phenotype and prognostic impact. |
| Q88044896 | U2AF1 mutation types in primary myelofibrosis: phenotypic and prognostic distinctions |
| Q45961967 | U2AF1 mutations in primary myelofibrosis are strongly associated with anemia and thrombocytopenia despite clustering with JAK2V617F and normal karyotype. |
| Q45309511 | Unique features of primary myelofibrosis in Chinese |
| Q100295687 | Unusual presentation of primary myelofibrosis with spontaneous bleeding after laparoscopic adrenalectomy: A case report |
| Q54611168 | Use of rifampin for treatment of disseminated tuberculosis in a patient with primary myelofibrosis on ruxolitinib. |
| Q93187681 | Utility of JAK2 V617F allelic burden in distinguishing chronic myelomonocytic Leukemia from Primary myelofibrosis with monocytosis |
| Q36779588 | Validation and comparison of contemporary prognostic models in primary myelofibrosis: analysis based on 334 patients from a single institution |
| Q68077860 | Vascular architecture and collagen type IV in primary myelofibrosis and polycythaemia vera: an immunomorphometric study on trephine biopsies of the bone marrow |
| Q83742042 | Whole-blood transcriptional profiling of interferon-inducible genes identifies highly upregulated IFI27 in primary myelofibrosis |
| Q33418847 | X-linked thrombocytopenia with thalassemia displays bone marrow reticulin fibrosis and enhanced angiogenesis: comparisons with primary myelofibrosis |
| Q50736181 | [A case of dermatomyositis associated with chronic idiopathic myelofibrosis]. |
| Q90616838 | [A case of gout secondary to primary myelofibrosis] |
| Q70802902 | [A case of megakaryoblastic leukemia showing features like primary myelofibrosis] |
| Q68674464 | [A case of primary myelofibrosis showing an interesting image on bone and bone marrow scintigraphy] |
| Q68732018 | [A case of primary myelofibrosis transformed into AMMoL after an excision of the spleen] |
| Q69849201 | [A case of primary myelofibrosis with nephrotic syndrome and pulmonary fibrosis terminating in acute leukemia] |
| Q82913991 | [A clinical analysis of six cases of portal hypertension secondary to primary myelofibrosis and review of literatures] |
| Q91294018 | [A study of clinical characteristics and prognosis of primary myelofibrosis patients with thrombocytopenia in varied degrees] |
| Q86041116 | [A study of prognostic value of cytogenetics in patients with primary myelofibrosis] |
| Q64047896 | [Actualities in the management of primary myelofibrosis] |
| Q73695643 | [Allogeneic bone marrow transplantation for primary myelofibrosis after splenectomy] |
| Q68997616 | [An autopsy case of primary myelofibrosis associated with extrahepatic portal venous obstruction and cavernous transformation around the biliary tree] |
| Q72066347 | [An autopsy case of primary myelofibrosis terminated in erythroleukemia after splenectomy] |
| Q71645771 | [An autopsy case of primary myelofibrosis with high value of circulating immune complexes, IgG(kappa) monoclonal gammopathy and extramedullary hematopoietic subcutaneous tumors] |
| Q68729206 | [Blastic crisis of primary myelofibrosis associated with multiple myeloblastomas ] |
| Q101045116 | [Bone marrow fibrosis in primary myelofibrosis in relation to myelodysplasia- and age-related mutations of hematopoietic cells] |
| Q77312373 | [Budd-Chiari syndrome and primary myelofibrosis] |
| Q72182947 | [Case of primary myelofibrosis] |
| Q72711576 | [Case of primary myelofibrosis] |
| Q86478957 | [Chinese expert consensus on the diagnosis and treatment of primary myelofibrosis （2015)] |
| Q91294014 | [Chinese guideline on the diagnosis and treatment of primary myelofibrosis (2019)] |
| Q71156264 | [Chronic idiopathic myelofibrosis. Study of 36 patients and review of the literature] |
| Q68748763 | [Chronic idiopathic myelofibrosis: clinical and pathological analysis of 30 cases] |
| Q85844147 | [Clinical features and prognostic analysis of 75 primary myelofibrosis patients] |
| Q54990082 | [Clinical features of essential thrombocythemia and primary myelofibrosis, depending on the molecular characteristics of disease]. |
| Q83878456 | [Clinical outcomes of allogeneic hematopoietic stem cell transplantation for adult primary myelofibrosis: retrospective analysis by Fukuoka BMT group] |
| Q73036339 | [Cutaneous vasculitis during primary myelofibrosis] |
| Q54569079 | [Development of polycythemia vera during chronic idiopathic myelofibrosis] |
| Q92723365 | [How I treat primary myelofibrosis] |
| Q50516107 | [Marked improvement of anemia during treatment with deferasirox in patients with primary myelofibrosis and acute myeloid leukemia with myelodysplasia-related changes]. |
| Q81093271 | [Pathophysiology of and therapy for primary myelofibrosis] |
| Q80757101 | [Physiopathology and treatment of primary myelofibrosis] |
| Q68809125 | [Primary myelofibrosis (osteomyelosclerosis). Current views on the pathogenesis, clinical course, diagnosis and therapy] |
| Q68710771 | [Primary myelofibrosis accompanied by various immunological abnormalities] |
| Q72449128 | [Primary myelofibrosis and osteolytic lesions] |
| Q95518995 | [Primary myelofibrosis complicated by acquired hemophilia A and subsequent development of acute myeloid leukemia] |
| Q72580912 | [Primary myelofibrosis in an infant--a case report and review of the literature] |
| Q88268000 | [Primary myelofibrosis in children involving the jaw: a case report] |
| Q53523704 | [Primary myelofibrosis showing megakaryoblastic crisis: a case report] |
| Q53495642 | [Primary myelofibrosis transforming into multiple subcutaneous monoblastoma--a case report] |
| Q68761774 | [Primary myelofibrosis with extramedullary haematopoiesis of the skin transformed into acute megakaryoblastic leukemia] |
| Q73016371 | [Primary myelofibrosis with fatal mesenteric arterial thromboembolism caused by antiphospholipid syndrome] |
| Q71313883 | [Primary myelofibrosis with positive coombs' test responding to prednisolone] |
| Q71313864 | [Primary myelofibrosis with severe bone pain] |
| Q70934924 | [Primary myelofibrosis with skin nodules terminating in leukemic transformation -- an autopsy case] |
| Q69520998 | [Primary myelofibrosis: description of a series of 53 patients] |
| Q83460444 | [Progress in treatment of primary myelofibrosis] |
| Q50730967 | [Study of 161 chronic idiopathic myelofibrosis patients for clinicopathological staging]. |
| Q68613482 | [Successful treatment of primary myelofibrosis by busulfan pulse therapy: report of a case] |
| Q82785977 | [The etiology, clinical features, and new therapy for primary myelofibrosis] |
| Q95497094 | [The role of driver and subclonal mutations in pathogenesis of primary myelofibrosis] |
| Q69703870 | [The use of MCNU to a patient of primary myelofibrosis complicated with pericardial effusion and proteinuria] |
| Q82262696 | [Traditional Chinese medicine combined with low-dose chemotherapy in treating chronic idiopathic myelofibrosis: a report of 10 cases] |
| Q53464656 | [Transformation into chronic myelomonocytic leukemia in a patient with primary myelofibrosis associated with severe hypoplasia: report of an autopsy case] |
| Q88268580 | [Transfusion independence achieved with pomalidomide therapy in a patient with primary myelofibrosis] |
| Q69551385 | [Treatment of primary myelofibrosis] |
| Q72629207 | [Trisomy of the long arm of chromosome in a patient with primary myelofibrosis during blast crisis] |
| Q42089573 | miR-494-3p overexpression promotes megakaryocytopoiesis in primary myelofibrosis hematopoietic stem/progenitor cells by targeting SOCS6. |
| Q42082695 | miRNA-mRNA integrative analysis in primary myelofibrosis CD34+ cells: role of miR-155/JARID2 axis in abnormal megakaryopoiesis |
| Q92354489 | t(15; 17) associated with primary myelofibrosis: a case report of an unusual clinical presentation and diagnostic dilemma |
| Mielofibrosi idiopatica cronica | wikipedia | |
| Mielofibrose idiopática | wikipedia |
Search more.